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Abstract
Small organic molecules, including small molecule based fluorescent probes, small molecule
based drugs or prodrugs, and smart multifunctional fluorescent drug delivery systems play
important roles in biological research, drug discovery, and clinical practices. Despite the
significant progress made in these fields, the development of novel and diverse small molecules
is needed to meet various demands for research and clinical applications. My Ph.D study focuses
on the development of novel functional molecules for recognition, imaging and drug release.
In the first part, a turn-on fluorescent probe is developed for the detection of intracellular
adenosine-5'-triphosphate (ATP) levels based on multiplexing recognitions. Considering the
unique and complicated structure of ATP molecules, a fluorescent probe has been implemented
with improved sensitivity and selectivity due to two synergistic binding recognitions by
incorporating of 2, 2‟-dipicolylamine (Dpa)-Zn(II) for targeting of phospho anions and
v

phenylboronic acid group for cis-diol moiety. The novel probe is able to detect intracellular ATP
levels in SH-SY5Y cells. Meanwhile, the advantages of multiplexing recognition design concept
have been demonstrated using two control molecules.
In the second part, a prodrug system is developed to deliver multiple drugs within one small
molecule entity. The prodrug is designed by using 1-(2-nitrophenyl)ethyl (NPE) as phototrigger,
and biphenol biquaternary ammonium as the prodrug. With controlled photo activation, both
DNA cross-linking agents mechlorethamine and o-quinone methide are delivered and released at
the preferred site, leading to efficient DNA cross-links formation and cell death. The prodrug
shows negligible cytotoxicity towards normal skin cells (Hekn cells) with and without UV
activation, but displays potent activity towards cancer cells (HeLa cells) upon UV activation.
The multiple drug release system may hold a great potential for practical application.
In the last part, a new photo-initiated fluorescent anticancer prodrug for DNA alkylating
agent mechlorethamine releasing and monitoring has been developed. The theranostic prodrug
consists a photolabile NPE group, an inactive form of mechlorethamine and a nonfluorescent
coumarin in one small molecule.

It is demonstrated that the prodrug shows negligible

cytotoxicity towards normal skin cells (Hekn cells) with and without UV activation, while the
original parent drug mechlorethamine can be photocontrol-released and induces effective DNA
cross-linking activity. Importantly, the drug release progress can be conveniently monitored by
the „off-on‟ fluorescence enhancement in cells. Moreover, the selective prodrug is not only cell
permeable but also nuclear permeable.

Therefore, the prodrug serves as a promising drug

delivery system for spatiotemporal control release and monitoring of an anticancer drug to obtain
the optimal treatment efficacy.
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Chapter 1
Introduction

1.1 Background
During the past several decades, vast progress has been achieved in the field of
fluorescent imaging which has significant impact on biomedical research, drug discovery,
and clinical practices. Fluorescent imaging allows the in vivo visualization of function
molecules (amino acids, coenzyme, carbohydrates, nucleosides, nucleotides, etc.) in their
intact and native psychological state with high sensitivity, selectivity, fast response time,
flexibility, biocompatibility and high spatial and temporal resolution [1-9]. It also provides
information about the structure and/or dynamics of living systems at a molecular level to
fully elucidate the roles of molecule of interest [1].
Despite the wide clinical applications of chemotherapeutic agents, their high
reactivity often accompanies high systemic toxicity and poor tumor selectivity, leading to
severe adverse effects which greatly hinder their therapeutic efficiency. In order to
alleviate or even overcome these limitations, various strategies have been developed such
as targeted therapies

[10]

, antibody-drug conjugates

[11]

, nano-particle drugs [10, 12], and

electrochemotherapy [13-19], etc. Among these therapies, prodrug strategy has provided an
alternative to redesign the drug molecule through a chemical approach to improve
multiple properties of the parent agents including bioavailability, duration of
pharmacological effects, stability, solubility, selectivity and to decrease toxicity [20].
An emerging area arises based on the integration of anticancer prodrug and
fluorescent reporter to achieve multi-functions [21]. The theranostic molecule is not only a
1

prodrug but also a fluorescent reporter that enables simultaneous monitoring and
delivering of the active drug to the target. These features are highly desirable for reaching
the optimal therapeutic efficiency in chemotherapy. Also, they emit fluorescence signals
that have potential applications for researchers to study the drug delivery process, to
control drug dosage, etc.

1.2 Fluorescent Probes
To explore and study the biological activities in the living system, the first step is to
visualize the dynamic processes of molecules involved. Therefore, various detection
methods have been utilized to transform biological information into other detectable
signals, examples includes radioactive tracers, EPR (electronic paramagnetic resonance)
probes, ion electrodes, etc[1]. Among them, fluorescent probes have received considerable
attention as they can provide dynamic information about the quantity and localization of
the molecule of interest with high sensitivity, selectivity, biocompatibility, sub-nanometer
spatial resolution (e.g., by fluorescence imaging microscopy), and sub-millisecond
temporal resolution, etc. [1-9, 22].
As the photophysical properties of fluorescent molecules are strongly affected by
their surrounding medium, they are generally applied for the investigation of
physicochemical, biochemical, and biological systems, thus known as fluorescent probes.
Fluorescent probe/sensor development was initially promoted by the blooming of
supramolecular chemistry and the advancement of photochemistry. Supramolecular
chemistry provides the basis of selective recognition between synthetic host molecules
and guest molecules using noncovalent interactions

2

[23-24]

, and photochemistry offers the

basic design principles how structure modification is related to photophysical properties.
Since then, a large number of fluorescent probes have been developed for targeting
various molecules and ions

[25-26]

, especially to meet the demand of biological and life

science.
Nowadays, an increasing number of versatile fluorescent molecules have been
developed to enable the noninvasive study of various biological processes

[27-30]

, at the

same time, advanced visualization methods have been utilized to give high quality
detection with a moderate cost. These achievements make fluorescent imaging as a new
exciting tool with great potential in basic research, drug discovery and clinical
applications.

1.2.1 Common Features of Fluorescent Probes
A typical fluorescent probe

[31-32]

consists of a fluorophore (signaling moiety) for

fluorescent signal generation, a receptor (recognition moiety) for analyte recognition, and
a spacer, linking them together. The recognition event, which takes place at the receptor,
and accordingly affects its topology and characters, is transduced through spacer to the
signaling moiety and consequently changes its photophysical characteristics. Based on
the differences in analyte recognition, fluorescent probes fall in two categories.
Conventional analyte recognition is based on noncovalent interactions, including
hydrogen bonding, π-π, donor-acceptor, electrostatic, hydrophobic, hydrophilic, and
coordination based interactions. When analyte recognition takes place where a covalent
bond is formed, it is reaction-based fluorescent probe (Figure 1.1). Both types of
fluorescent probes are essential for the detection of different types of analytes.
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Figure 1.1. Conventional sensory systems and reaction-based sensory systems.

1.2.1.1 Fluorophore (Signaling Moiety)
Organic dyes are commonly used fluorophores which cause fluorescent emission
ranging from the ultraviolet to the near-infrared in the electromagnetic spectrum. Upon
excitation, a molecule undergoes fast energy absorption (≈10 -15s) and is excited from the
ground state S0 (the most common state at room temperature for most organic species) to
the excited singlet state (S1). Upon relaxation from S1 to S0, fluorescence is generated in
the form of light (Figure 1.2). When the receptor interacts with its surroundings,
information is transduced by the linker to the fluorophore and alters its fluorescence
properties (such as absorption and emission spectra, quantum yield, lifetime, etc.). By
measuring the differences in the fluorescence properties, spatial and temporal information
of the microenvironment (such as ion and molecular concentration, polarity, etc.) can be
monitored.
4

Figure 1.2. Jablonski diagram.

1.2.1.2 Receptor (Recognition Moiety)
For practical applications, a fluorescent probe should be able to detect a small amount
of a particular analyte among various other species existing in the surrounding, therefore,
specificity and sensitivity become two important parameters for fluorescent probe design.
The specificity and sensitivity of a probe are designed based on the specific interactions
or reaction between the receptor and the analyte.

1.2.1.3 Spacer (Linker)
Depending on the underlying photophysical mechanism, the spacer can be saturated
to disconnect the electronic systems of chromophore and binding unit or unsaturated to
couple these electronic subsystems.

5

1.2.2 Design Principles of Fluorescent Probes
A fluorescent probe converts non-optical information into optical signals based on the
alterations in the photophysical properties of the fluorophore. Different fluorophores have
different energy transfer mechanisms to affect fluorescence properties. Listed in the
followings are some of the most commonly used photoinduced processes that lead to
photophysical changes.

1.2.2.1 Photoinduced Electron Transfer (PET)
One of the most extensively employed mechanisms in the design of fluorescent
probes is based on photoinduced electron transfer (PET) process (Figure 1.3)

[33-36]

. In a

fluorescent molecule, an electron is promoted from HOMO to LUMO upon light
absorption. Subsequent decay back to HOMO produces fluorescence emission. However,
the fluorescence emission process can be disrupted by introducing a quencher to the
system. The quencher works by either reductive electron transfer or oxidative electron
transfer. In the unbounded state, a fast electron transfer (from HOMO of reductive
quencher to the HOMO of the excited fluorophore, known as reductive quench; from
LUMO of the fluorophore to the LUMO of the excited fluorophore, known as oxidative
quench) quenches the fluorescence of the system. The fluorescence emission can be
regained by slowing down or switching off the electron transfer process. It is usually
realized by analyte binding at the receptor to modulate the redox potential of the
quencher.

6

Figure 1.3. PET mechanism. (a) reductive PET; (b) oxidative PET.

(a)

(b)

1.2.2.2 Photoinduced Charge Transfer (PCT)
Photoinduced charge transfer is another widely applied process in the design of
fluorescent probes [37-38]. When a fluorophore contains an electron-donating group (EDG)
7

conjugated to an electron-withdrawing group (EWG), it undergoes intramolecular charge
transfer (ICT) from the donor to the acceptor upon light absorption. The consequent
change in dipole moment results in a Stokes shift which depends on the
microenvironment of the fluorophore. When an analyte binds to an electron-donating
group, the electron-donating ability is reduced, the decrease in conjugation leads to a blue
shift of the absorption spectrum and a decrease in extinction coefficient. Conversely, the
binding between an analyte and an electron-withdrawing group leads to an increase in
conjugation, i.e. a red shift of the absorption spectrum and an increase in extinction
coefficient. In addition to all these shifts, changes in quantum yields and lifetimes are
often observed.

1.2.2.3 Fluorescence Resonance Energy Transfer (FRET)
Fluorescence resonance energy transfer is one kind of "Förster resonance energy
transfer" (FRET) when both the donor and the acceptor are fluorophores[39]. When there
are interactions between a donor moiety and an acceptor moiety, non-radiative excitaion
energy is transferred from the donor to the acceptor. It often takes place if the emission
spectrum of the donor overlaps with the absorption spectrum of the acceptor, and that
several vibronic transitions in the donor have practically the same energy as the
corresponding transitions in the acceptor. Such transitions are dipole-dipole coupled in
resonance (Figure 1.4). The surrounding environment changes the spectra properties of
either donor or acceptor, or the space between donor and acceptor, thus results in a
change of the spectra properties of acceptor or donor.

8

Figure 1.4. FRET mechanism.

1.2.2.5 Excimers and Exciplex Formation
Excimers are dimers in the excited state. They are formed by collision between an
excited molecule and an identical unexcited molecule

[40-41]

. Dual fluorescence is

observed with a monomer band and a structureless broad band at longer wavelength due
to excimer formation. When a fluorescent probe contains two fluorophores whose mutual
distance is affected by analyte complexation, [39] recognition of this analyte can be
monitored by the monomer/eximer fluorescence-intensity ratio.
Exciplexes are another form of excited-state complexes. They are formed by collision
of an excited molecule (electron donor or acceptor) with an unlike unexcited molecule
(electron acceptor or donor).

Excimer formation: M* + M ←→ (MM)*
Exciplex formation: D* + A ←→ (DA)*; A* + D ←→ (DA)*

1.3 Cancer Chemotherapy
Cancer, characterized by the uncontrolled cell growth [42-43], is currently the second
9

most common cause of deaths in the US, accounting for nearly one in every four deaths
[44]

. Among the management options such as surgery, radiation therapy and palliative care,

chemotherapy is currently the leading treatment option to treat many cancer types,
especially for the systematic treatment of metastasis

[45]

. Chemotherapeutic agents are

small molecule drugs that interfere with DNA replication, repair, translation or cell
division, thus inhibit cancerous cell proliferation

[46]

. Clinical chemotherapeutic agents

include DNA alkylating agents, anti-metabolites, anti-microtubule agents, topoisomerase
inhibitors and cytotoxic antibiotics, among which, DNA alkylating agent is one of the
most prominent class of anticancer agents due to their high degree of reactivity [47-49].
Being the first modern cancer chemotherapeutic agent in the DNA alkylating family,
nitrogen mustard type anticancer drug has attracted lots of investigations and is one of the
most heavily employed anticancer agents in use today [48-49]. For example, Valchlor by
Ceptaris Therapeutics, is a gel formulation of mechloethamine hydrochloric salts
approved by US Food and Drug Administration in August 2013 for the treatment of Stage
IA and IB mycosisfungoides-type cutaneous T-cell lymphoma (Scheme 1.1a). Leukeran
by GlaxoSmithKline, contains DNA alkylating agent chlorambucil is currently used for
treating chronic lymphocytic leukemia (Scheme 1.1b). Both of these nitrogen mustard
type anticancer drugs bear a reactive N,N-bis-(2-chloroethyl)amine to form interstrand
cross-links (ICLs) between DNA double strands, mostly at the guanine N-7. To carry
sufficient reactivity, the nitrogen mustard type drug must have enough electron density
on the amine nitrogen to form the highly electrophilic aziridinium ring through
intramolecular displacement of the chloride. This highly electophilic aziridinium ring is
the actual reactant with DNA bases in forming covalent bonds, shutting down DNA
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replications and transcriptions, and consequently leading to mutations and/or cell death
(Scheme 1.2) [48].

Scheme 1.1 Nitrogen mustard type chemotherapeutic agents
(a) Valchlor (Mechloethamine hydrochloric salt)

(b) Leukeran (Chlorambucil)

Scheme 1.2 Mechanism of action of nitrogen mustard type anticancer drug

Besides the nitrogen mustard type DNA interstrand cross-links (ICLs) inducing
agents, quinone methide derivatives have displayed good activities as antitumor agents or
antibiotics. Its reactivity was mainly caused by its forming highly polarized structure to
react with nucleophiles, especially DNA bases at the exocyclic methylene group to form
benzylic adducts[50] (Scheme 1.4). Various quinone methide derivatives have been
11

developed as DNA intercross linking agents. For example, Mitozytrex or Mutamycin,
containing mitomycin C, is a commercially available chemotherapeutic agent for the
treatment of stomach cancer, pancreas cancer and other types of cancer

[51-52]

(Scheme

1.3a). Anthracycline is a class of very effective anticancer drugs that showed potent
activity against a wide spectrum of cancer types

[53-54]

. Their antitumor activities are

caused by the formation of QMs which undergo tandem reactions to form DNA crosslinks

[55-56]

, see the first example of anthracycline discovered – Daunomycin

(Daunorubicin) (Scheme 1.3b).

Scheme 1.3 Quinone methide derivatives
(a) Mitozytrex or Mutamycin (Mitomycin C)

(b) Daunomycin (Daunorubicin)

Scheme 1.4 Mechanism of action of quinone methide type anticancer drug
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Despite the wide applications of the nitrogen mustard type and quinone methide type
chemotherapeutic agents, their high degree of reactivity came alone with low selectivity
lead to high systematic toxicity and limited therapeutic indices
life-threatening side effect with little therapeutic effects

[20]

[57-58]

, i.e. severe or even

. Therefore, prodrug strategy

becomes a very important option in designing less cytotoxic anticancer drugs.

1.3.1 Nitrogen Mustard Based Prodrugs
Anticancer prodrugs are the less active and less cytotoxic forms of drug derivative
that has some barrier to its utility as an effective drug, after activation or metabolism, it is
preferentially released at the site of action [20, 59-60]. In general, a prodrug is designed by
attachment of the active moiety (parent drug) through an activatable linkage to the
“promoiety” [61] (Scheme 1.5). The promoiety is designed to improve selectivity based on
the differences between cancer cells and normal cells. There are generally three strategies
in designing the promoiety: 1. Active targeting, promoiety is designed by taking
advantage of the differences in cell surface makers such as receptor or antigen between
tumor cells and normal cells. 2. Passive targeting, promoiety is designed by taking
advantage of the differences in biochemical or physiological properties between tumor
cells and normal cells such as pH, oxidative stress, etc. 3. External activator, promoiety is
13

designed based on external stimuli such as light or heat to achieve direct control of drug
release in the targeted area [61].

Scheme 1.5 An illustration of the prodrug concept

As nitrogen mustard type anticancer drugs bear very high reactivity, much effort has
been devoted to making prodrugs to improve the clinical utilities of nitrogen mustard
type anticancer agents. For example, cyclophosphamide (CPA)

[62-64]

and its isomer

ifosfamide (IFA) [65] are prodrugs that can be activated in vivo by cytochrome P450 to
release the ultimate DNA alkylating agent phosphamide mustard. Based on the parent
drug chlorambucil, a number of lipophilic prodrugs have been developed. Examples
include clinical approved prednimustine, the ester of prednisolone-chlorambucil
conjugate, is able to selectively target tumor cells with cancer specific receptors

[66-67]

.

Bestrabucil, the benzoate of the estradiol-chlorambucil conjugate, has been approved for
the treatment of estrogen-receptor positive breast cancer

[68-69]

. Other examples include

the dipeptide prodrug of melphalan, J1 (L-melphalanyl-p-L-fluorophenylalanine ethyl
14

ester, which can be activated by aminopeptidase to release melphalan. The selectivity of
prodrug J1 is designed based on the elevated aminopeptidase activity in the plasma of
cancer patient. It is currently in phase I clinical trial for the treatment of disseminated
solid tumors in adults

[70-73]

. Another prominent example is hypoxia activated prodrugs

for the selective treatment of solid tumors. PR-104, currently under clinical trial, works
converting to PR104A, subsequently to PR-104H and PR-104A metabolites under
hypoxic conditions [74]. To the best of our knowledge, no light activated nitrogen mustard
type prodrug has been reported.

Scheme 1.6 Structure of nitrogen mustard type prodrugs
(a) cyclophosphamide (CPA)

ifosfamide (IFO)

(b) Prednimustine

(c) Bestrabucil

15

(d) J1 (L-melphalanyl-p-L-fluorophenylalanine ethyl ester

(e) PR-104

1.3.2 O-quinone Methide (o-QM) as Inducible DNA Alkylating Agent
With the fact that quinone methide derivatives are excellent DNA alkylating agents,
they can be generated in different ways. As is reported, they can be generated by photoirradiation

[75-77]

, oxidation

[78-81]

, or fluoride inducing

[55, 82-83]

. Recently, biphenyl

biquaternary ammonium derivatives have been reported to have much more potent ISC
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activity than the traditional phenyl biquaternary ammonium upon photochemical
activation [50] (Scheme 1.7a). Its high reactivity is caused by the formation of bisquinone
methide intermediate instead of monoquinone methide intermediate. Meanwhile, its
structural affinity with a DNA helix improves DNA alkylating potency. Based on the
previous report, Zhou group developed a phenyl selenide biphenyl compound which can
be efficiently oxidized by periodate to release quinone methide for DNA bisalkylation

[81]

(Scheme 1.7b).

Scheme 1.7 Biphenyl biquaternary ammonium based quinone methide prodrug
(a) light activated quinone methide prodrug

(b) oxidation mediated quinone methide prodrug

1.4 Multiple Drug Release Chemotherapy
Many diseases, especially cancer, usually cannot be fully cured by a single drug
treatment due to the pathological complexity. However, multiple drug chemotherapy may

17

have enhanced therapeutic efficiency compared with traditional chemotherapy

[84]

.

Compared with traditional chemotherapy, multiple drug chemotherapy is more potent so
that lower dosage is administrated, leading to suppression of severe side effect.
Considerable efforts have been devoted to nano-material based multidrug delivery system,
but limited progress was made in small molecule based multidrug delivery system [84].
The combination of prodrug design and multiple drug release to the desired site
would be potentially useful. In the field of small molecule based multiple drug delivery
system, dual acting antibiotics have been developed previously

[85]

, only very few dual

acting anticancer prodrugs were developed. Back in 1999, Smyth and coworkers made a
novel class of β-lactamase-dependent prodrug using cephalosporin as prodrug nucleus.
Through enzyme catalyzed hydrolysis, two structural distinct components – 3‟ acetoxy
group and the side chain sulfur-attached S-amino moiety was released

[86]

. Based on the

same cephalosporin prodrug nucleus structure, further modification gave a prodrug that
inhibits estrogen production in hormone-dependent breast cancer by the release of
aminoglutethimide (an aromatase inhibitor) at the 3‟-position and coumate (a sulfatase
inhibitor) as the S-aminosulfenimine

[87]

. The synergistic effect of two drugs released at

the same site may become an alternative approach for chemotherapy.

Scheme 1.8 Cephalosporin-based dual-release prodrug
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1.5 Combining Fluorescent Imaging with Prodrug Therapy
Despite the traditional role of fluorescent molecules in detecting small molecules,
they have found many new applications in the field of life sciences as a versatile tool.
Nowadays, with the development of drug delivery system, people have developed a novel
type of fluorescent imaging agent that carries dual functions. On the one hand, it is a
prodrug that can be activated by various biological stimuli to release parent drug to
improve selectivity and reduce cytotoxicity. On the other hand, the prodrug itself is an
imaging agent that emits fluorescence light upon drug release. These properties facilitate
the monitoring of drug delivery process, help to diagnose diseases, and guide in
controlling the dosage level in a spatial and temporal manner.
Among various studies in this field, a large amount of the multifunctional anticancer
drug delivery systems (DDSs) to date are based on nano-materials

[21, 88-93]

, only a few

examples of small-molecule based drug delivery system have been reported[94-99]. In 2011,
Perez et al. developed a cell-specific theranostic prodrug for cancer imaging and therapy.
Taking advantage of the over-expressed folic acid receptors on many types of tumor cells,
the authors synthesized folate doxorubicin conjugate. Both the fluorescence and
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cytotoxicity are quenched by the covalently linked folic acid, through targeted cellular
uptake, disulfide bond undergoes glutathione mediated dissociation and nuclear
translocation to display enhanced fluorescence, meanwhile release doxorubicin

[94]

(Scheme 1.9a). In 2012, Kim et al. designed a theronostic prodrug using a RGD peptide
as a cancer-targeting unit, a naphthalimide moiety as a fluorescent reporter to release a
model anticancer agent camptothecin (CPT). Through RGD-dependent endocytosis, it is
preferentially taken up by α vβ3 integrin rich U87 cells over αvβ3 integrin deficient C6
cells. Subsequently, disulfide bond cleavage takes place in the cytoplasm, resulting in
CPT release and a red-shifted fluorescence emission [96](Scheme 1.9b). In 2012, Shabat et
al. reported a novel molecular design of a prodrug based on a self-immolative linker
attached to a pair of FRET fluorophores and chemotherapeutic agent camptothecin. The
prodrug is recognized by enzyme penicillin-G-amidase to release the parent drug
camptothecin, meanwhile, the disassembly of the prodrug gave off fluorescent signals
which provide information about the actual location and amount of drug release
[97]

(Scheme 1.9c). In 2013, with a similar strategy, Kim et al. made a gemcitabine-

coumarin-biotin conjugate in which biotin is the cancer targeting unit, gemcitabine (GMC)
is the active drug, and coumarin is the fluorescent reporter. Upon uptake into the tumor
cells, abundant thiols in tumor cells lead to disulfide bond cleavage, and subsequently
release gemcitabine drug and cause fluorescence enhancement

[99]

(Scheme 1.9d). In 2013,

Zhou et al. developed a fluorescent activatable anticancer prodrug. It contains a
naphthalimide as fluorescent reporter and a chloroambucil as a potent anticancer drug
which are linked by a disulfide link. Through intracellular thiol mediated disulfide
cleavage, free active DNA alkylating agent was released, meanwhile, produced a red-
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shifted fluorescent signal

[98]

. The combination of fluorescent imaging and prodrug

therapy makes a powerful tool in enhancing therapeutic effect as well as providing
fluorescent information about drug delivery.

Scheme 1.9 Examples of combing fluorescent imaging with prodrug strategy
(a) Folic acid mediated activation

(b) RGD peptide mediated activation

(c) Penicillin-G-amidase mediated activation
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(d) Biotin mediated activation

(e) Thiol mediated activation

1.6 Research Summary
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Despite the enormous efforts made in the field of fluorescence imaging and
anticancer prodrug design, there are significant challenges facing upon us. On the one
hand, novel fluorescent probes to detect function molecules in the living system with
good selectivity and sensitivity are needed to meet the requirement of biochemical
research. On the other hand, new anticancer prodrugs with high selectivity and low
cytotoxicity are in great demand to fight against cancer. Moreover, the combination of
fluorescent imaging and prodrug chemotherapy will not only be a good candidate in drug
discovery but also be a versatile tool in biomedical research. Therefore, I will detail my
efforts in the above mentioned areas. Chapter 2 presents a novel fluorescent probe for
detection of ATP in biological system. Chapter 3 reports a photo-triggered multiple drug
releasing prodrug. Chapter 4 focuses on the development of a multi-functional phototriggered fluorescent prodrug for imaging and drug release.
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Chapter 2
Development of Fluorescent Probe for ATP

2.1 Background
Adenosine-5'-triphosphate (ATP) is a multifunctional nucleoside widely existing in
biological systems. Being a universal energy source for various cellular functions in
almost all living systems, it is also involved in many other biological processes [1]. For
example, ATP acts as a phosphate donor in kinase-catalyzed protein phosphorylation. It
plays an important role as signaling substances in periphery as well as in central nervous
systems [2]. Recently, it was found that ATP plays a vital role in mediating distinct forms
of sensory transduction within the central nervous system [3]. Furthermore, ATP released
from human neutrophils helps to amplify chemotactic signals and direct cell orientation [2].
The ability to significantly detect the local or dynamic ATP concentrations in biological
environment is critical for fully elucidating its roles in living systems.
In recent years, much effort has been devoted to the development of fluorescent
probes for ATP detection [4-21]. The ATP structure contains a tri-phospho anion connected
by a ribose with an adenine base (Figure 2.1). However, most of ATP probes focused on
the recognition of tri-phospho anion. In 2002, it was first discovered by the Hamachi
group that anthracene derivatives bearing Zn(II)-dipicolylamine selectively binds to
phosphorylated chemical species, and causes fluorescence change

[22]

. Later, they

published a turn-on fluorescent probe for ATP based on the previous discovery

[21]

. It

contains fluorescein as fluorophore with two Zn(II)-dipicolylamine moieties for binding
with tri-phospho anion on ATP (Scheme 2.1).
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Figure 2.1 ATP structure
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Scheme 2.1 ATP probe developed by the Hamachi group

To achieve better sensitivity and selectivity, we have developed a turn-on fluorescent
probe with multiplexing recognitions towards ATP - 2, 2‟-dipicolylamine (Dpa)-Zn(II)
strongly binds to phospho anions, and phenylboronic acid binds to a cis-diol on the ribose.
Firstly, we demonstrated that the probe was able to response to ATP with good sensitivity
and selectivity in aqueous buffer at physiological pH. Furthermore, the probe was applied
for the monitoring of intracellular ATP levels in SH-SY5Y cells. In the end, we
compared the probe with two control compounds and showed the advantages of
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multiplexing recognitions over traditional fluorescent probe bearing a single recognition
group.

2.2 Design Strategy
The unique structure of ATP promoted us to apply multiplexing recognitions to detect
ATP aimed at enhancing selectivity and sensitivity. Unlike most of the simple analytes,
ATP has a relatively complicated structure with three parts. A purine base (adenine)
attached to the 1‟ carbon atom and three phosphate groups attached to the 5‟ carbon atom
of pentose sugar (ribose). In aqueous solution at physiological pH, the triphosphate
residue exists as a tetra-charged anion

[23]

. We proposed that a fluorescent probe having

dual interactions with both tetra-charged triphosphate ion and ribose would exhibit
stronger and more specific binding than single interaction with either phospho ion or
ribose. Taking advantage of the previous discovery that 2, 2‟-dipicolylamine (Dpa)-Zn(II)
binds strongly to phospho ions [22], and the relatively strong and specific binding affinity
between phenylboronic acid and a cis-diol which is an essential component in
monosaccharide

[24-29]

, we incorporated into the fluorescent probe a 2, 2‟-dipicolylamine

(Dpa)-Zn(II) moiety for tri-phospho ion recognition and a phenylboronic acid moiety for
ribose binding. As is shown in Scheme 2.2, probe 2-1 was composed of a polyamine
appended anthracene as the fluorophore with two receptors connected to the amine
groups at both end of the anthracene. The lone pair electrons on both of the unbounded
amines are expected to quench the fluorescence of anthracene by PET pathway, resulting
in non-fluorescence. Upon binding of phospho ion to 2, 2‟-dipicolylamine (Dpa)-Zn (II)
moiety, PET pathway from one of the amine was blocked, resulting in weak fluorescence.
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Upon binding of cis-diol to phenylboronic acid, PET pathway of the other free amine was
blocked, also resulting in weak fluorescence. The fluorescence can be turned on only if
both PET pathways of the amines were blocked by binding with phospho ion and ribose,
respectively. Thus, ATP is expected to turn on the fluorescence with its structure bearing
both a triphosphate moiety and a ribose moiety (Scheme 2.2). In order to achieve good
selectivity with ATP against ADP and AMP, the proper length between phospho ion and
ribose diol should be considered. From the structure of these molecules, ATP could
interact with the probe better than ADP and AMP with a longer distance between
phospho ion and ribose diol, as well as stronger binding between 2, 2‟-dipicolylamine
(Dpa)-Zn (II) and triphosphate than monophosphate and diphosphate.

Scheme 2.2 Proposed ATP binding mechanism

To verify the hypothesis that both the 2, 2‟-dipicolylamine (Dpa)-Zn (II) moiety and
the phenylboronic acid group contribute to ATP binding, we designed control compounds
2-2 and 2-3 (Figure 2.2). Control 2-2 has the similar structure as probe 2-1 except it
contains a phenyl group instead of a phenylboronic receptor. Control 2-3 has the similar
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structure as probe 2-1 except it contains a hydroxyl methyl group instead of the 2, 2‟dipicolylamine (Dpa)-Zn(II) moiety. Based on our hypothesis, upon the addition of ATP,
we expect to see strong fluorescence of probe 2-1, compared with no or weak
fluorescence with control compounds 2-2 and 2-3.

Figure 2.2 Structure of probe 2-1, control compound 2-2 and control compound 2-3.

2.3 Synthesis
The synthesis of probe 2-1 was outlined in Scheme 2.3. Using the typical procedure
for making compound 2-4 10-(hydroxymethyl)anthracene-9-carbaldehyde through two
steps, the hydroxyl group was subsequently protected as silyl ether. Reductive amination
gave 2-7 in good yield, followed by Boc protection of the secondary amine. The
introduction of 2, 2‟-dipicolylamine (DPA) was conducted by making methyl sulfate as a
good leaving group. After deprotection of Boc, phenylboronic acid moiety was
successfully incorporated into the anthracene backbone. In the end, Zn(II) was
coordinated to DPA by stirring with zinc nitrate THF solution for 30 min.
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Scheme 2.3 Synthesis of probe 1

Reaction conditions: (i). NaH, (CH3)3SI, dry DMSO, r.t., under dark environment, 1.5 h. (ii). LiBr,
dry MeCN, 60 ºC, under dark environment, 16 h. (iii). TBSCl, imidazole, dry DMF, r.t., 14 h. (iv).
CH3NH2 in methanol, NaBH4, 6h. (v). Boc2O, anhydrous ethanol, 5 h. (vi). TBAF, THF, r.t. 3 h.
(vii). MsCl, dry CH2Cl2, TEA, 0 ºC to r.t. (viii). 2,2‟-dicopicolylamine, MeCN, reflux, 36 h. (ix).
TFA, CH2Cl2, r.t. 2h. (x). 2-(2-(bromomethyl)phenyl)-5,5-dimethyl-1,3,2-dioxaborinane, K2CO3,
THF, reflux, 39 h. (xi). Zn(NO3)2 solution, THF, r.t. 0.5 h.

The synthesis of control compound 2-2 was similar to that of probe 2-1 except the
coupling reaction was conducted with (bromomethyl)benzene instead of 2-(2(bromomethyl)phenyl)-5,5-dimethyl-1,3,2-dioxaborinane (Scheme 2.4). The synthesis of
control compound 2-3 was outlined in Scheme 2.5, starting from compound 3, reductive
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amination afforded compound 13 which was further converted to control compound 2-3
by reaction with 2-(2-(bromomethyl)phenyl)-5,5-dimethyl-1,3,2-dioxaborinane.

Scheme 2.4 Synthesis of control 2-2

Reaction conditions: (i). (bromomethyl)benzene, K2CO3, THF, reflux, 24 h, separated by reverse
phase HPLC. (ii). Zn(NO3)2, THF, r.t. 0.5 h.

Scheme 2.5 Synthesis of control 2-3

Reaction conditions: (i). CH3NH2, NaBH4, ethanol, r.t. 6 h. (ii). 2-(2-(bromomethyl)phenyl)-5,5dimethyl-1,3,2-dioxaborinane, K2CO3, THF, reflux, 39 h.

2.4 Results and Discussions
2.4.1 Evaluation of Probe 2-1 in HEPES Buffer
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With probe 2-1 in hand, we first tested its fluorescence properties and established the
optimal test conditions. Notably, probe 2-1 showed good solubility in water. Accordingly,
all the experiments were performed in HEPES buffer (10mM, pH = 7.2). As designed,
probe 2-1 exhibited weak fluorescence in the absence of ATP which can be explained as
the lone pair electrons from the two amine atoms (amine attached to 2, 2‟-dipicolylamine
(DPA)-Zn(II) and phenyl boronic acid, respectively) quenched the fluorescence by PET
pathway. The fluorescence intensity enhancement was observed with as low as 0.01 μM
ATP. The characteristic peaks of anthracene fluorophore between 410nm and 480nm
continued to increase with increasing amount of ATP, maximum fluorescence emission
was reached with 30 µM of ATP. Meanwhile, the relationship between ATP
concentration and fluorescence intensity was investigated. The fluorescence intensity at
415 nm was proportional to ATP concentration (Figure 2.1).

(a)

(b)
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10 uM
0.5 uM
0.3 uM
0.2 uM

100

0.01 uM
free probe

50

Fluorescence intensity

Fluorescence intensity

150

150
100
50
0

0
365

415
465
Wavelength (nm)

0

515

10
20
ATP concentration (uM)

30

Figure 2.1 Effect of ATP concentrations on the fluorescence emission of probe 2-1. Probe 2-1
(10 µM) was studied in a HEPES buffer (pH = 7.2, 0.01 M) at room temperature in the absence
and presence of ATP at different concentrations (10 nM~30 µM). After 3 min, the reaction
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solution was immediately sampled for fluorescence measurement. (a). fluorescence spectra. (b).
fluorescence intensity at 415 nm was plotted vs. ATP concentrations.

Based on the results above, we subsequently conducted the selectivity test of probe 21 towards ADP, AMP, other phosphates and sugar in aqueous solution. The fluorescence
intensity increased moderately upon the addition of ADP. Very weak fluorescence
intensity was observed upon the addition of AMP and other compounds (Figure 2.2).
These results demonstrated that probe 2-1 showed a certain level of selectivity for
discriminating ATP from ADP, AMP, phosphates, and mannose.
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Figure 2.2. The selectivity of probe 2-1 towards ATP and other species. 10 µM probe 2-1,
prepared from a stock solution of MeCN, was studied in a HEPES buffer (pH = 7.2, 0.01 M) at
room temperature in the presence of 10 µM various analytes (1 equiv.). After 3 min, reaction
solution was sampled for fluorescence measurement. (a). fluorescence spectra. (b). Fold of
fluorescence enhancement for various species at λem = 415 nm.
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2.4.2 Fluorescent Detection of Intracellular ATP Levels
We further investigated the biological applications of probe 2-1 in living cells. Probe
2-1 was incubated with neural cancer cells SH-SY5Y cells, 30 min after the extracellular
addition of ATP, fluorescence imaging was conducted. Results showed that stronger
fluorescence signals were observed with increased ATP concentrations from no ATP, 50
µM ATP, to 100 µM ATP addition (Figure 2.3a-c). Furthermore, the ATP deficient
condition was created when SH-SY5Y cells were treated with KCN (0.1mM), an
inhibitor for glycolysis under glucose starvation conditions, a substantial decrease in
fluorescence was observed (Figure 2.3 d). All the results demonstrated that intracellular
ATP level was reflected by the fluorescence signals of probe 2-1 in live cells.

a

b

c

d

Figure 2.3. (a) Fluorescence images of SH-SY5Y cells stained with 10µM probe 2-1. (b)
Fluorescence images of SH-SY5Y cells stained with 10µM probe 2-1 upon addition of 50µM
ATP. (c) Fluorescence images of SH-SY5Y cells stained with 10µM probe 2-1 upon addition of
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100µM ATP. (d) Fluorescence images of SH-SY5Y cells stained with 10µM probe 2-1 after
treatment of 0.1 mM KCN in the absence of glucose.

2.4.3 Mechanism Study of Probe 2-1 Comparing with Control Compounds 2-2 and
2-3
To verify our hypothesis that multiplexing recognition gave better fluorescence
responses compared with traditional fluorescent probes with only a single recognition
group, we tested the fluorescence responses of control 2-2 and control 2-3 towards ATP
in comparison with probe 2-1. Both the control compound 2-2 and control 2-3 were
tested in the same condition as of probe 2-1. Compound 2-2 showed weaker fluorescence
enhancement upon the addition of ATP in the buffer as well as poor resolution in cell
imaging, both of which proved that the phenylboronic acid moiety is playing a role in
ATP binding (Figure 2.4 and Figure 2.6a). Compound 2-3 showed no fluorescence
enhancement upon the addition of ATP in buffer and no fluorescence signal in the cell
imaging (Figure 2.5 and Figure 2.6b), which proved our design strategy that 2,2‟dicopicoylamine Zn(II) moiety was also essential for ATP binding. On the other hand,
probe 2-1 showed higher sensitivity both in buffer and cellular imaging. The results
above proved that with two recognition groups binding phospho ion and cis-diol,
respectively, probe 2-1 exceeds control compound 2-2 and 2-3 in its sensitivities for the
detection of ATP molecules.
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Figure 2.4. Emission spectra of probe 2-1 and control compound 2-2 (10 µM) towards ATP.
Both probe 2-1 and control compound 2-2 were prepared from a stock solution of MeCN, and
were studied in a HEPES buffer (pH = 7.2, 0.01 M) at room temperature in the absence and
presence of 10µM ATP. After 3 min, the reaction solution was sampled for fluorescence
measurement. Dashed blue line: control compound 2-2; dashed orange line: control compound 22 after addition of ATP; solid red line: probe 2-1; solid green line: probe 2-1 after addition of
ATP.
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515

Figure 2.5. Emission spectra of probe 2-1 and control compound 2-3 (10 µM) towards ATP.
Both probe 2-1 and control compound 2-3 were prepared from a stock solution of MeCN, and
were studied in a HEPES buffer (pH = 7.2, 0.01 M) at room temperature in the absence and
presence of 10 µM ATP. After 3 min, the reaction solution was sampled for fluorescence
measurement. Dashed green line: control compound 2-3; dashed red line: control compound 2-3
after addition of ATP; solid orange line: probe 2-1; solid blue line: probe 2-1 after addition of
ATP.

a

b

c

Figure 2.6. (a). Fluorescence images of SH-SY5Y cells stained with 10µM probe 2-1. (b).
Fluorescence images of SH-SY5Y cells stained with 10µM control compound 2-2. (c).
Fluorescence images of SH-SY5Y cells stained with 10uM control compound 2-3.

2.5 Summary
In conclusion, we developed a fluorescent probe 2-1 for monitoring ATP based on
multiplexing recognition. The probe worked in a pH=7.2 aqueous buffer, and showed
6.13 fold fluorescence enhancement upon ATP binding. It also exhibited a certain degree
of selectivity among other structurally similar compounds including ADP, AMP,
pyrophosphate ion, phosphate ion and mannose. It has been successfully applied in
detecting intracellular ATP levels. Meanwhile, we made two control compounds which
were tested in the same condition as probe 2-1. Comparing with control compounds,
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probe 2-1, designed with multiplexing recognition, showed stronger fluorescence turn-on
effect in buffer and gave better resolution in cell imaging. All the results demonstrated
that multipoint recognition strategy may act as an effective approach in designing probes
with higher resolution and better selectivity.

2.6 Experimental Section
General Information
Commercial reagents were used as received, unless otherwise stated. Merck 60 silica gel
was used for chromatography, and Whatman silica gel plates with fluorescence F254
were used for thin-layer chromatography (TLC) analysis. 1H and

13

C NMR spectra were

recorded on Bruker tardis 300 or Bruker Avance 500. Data for 1H are reported as follows:
chemical shift (ppm), and multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m
= multiplet). Data for

13

C NMR are reported as ppm. Mass Spectra were obtained from

University of New Mexico Mass Spectral facility.

Synthesis of Probe 2-1, Control Compounds 2-2 and 2-3:
Compound 2-1 was synthesized following the procedures in Scheme 2.3.

O

O

Trans-dispiro[oxirane-2,9’(10’H)-anthracene-10’,2”-oxirane] (2-4).
To a stirred mixture of 60% NaH (900 mg, 22.5mmol), and anthraquinone (2080mg,
10mmol) in 60mL dry DMSO ar r.t. was added dropwise a solution of
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trimethylsulfonium iodide (4590mg, 22.5mmol) in 40mL of dry DMSO over a period of
1 hour. The reaction was conducted in dark and under nitrogen protection. The reaction
mixture was stirred for 5 hours until no anthraquinone remained monitored by TLC. The
mixture was poured into 170mL of ice water, and filtered after standing for 0.5 hour. The
residue was collected and washed with water to give the product as light yellow solids,
which were used in the following reactions without further purification.

HO

CHO

10-(hydroxymethyl)anthracene-9-carbaldehyde (2-5).
To a solution of lithium bromide (1203mg, 46.2mmol) in 150 mL of dry acetonitrile was
added compound 2-4 (2360mg, 10mmol). The reaction mixture was stirred at 60 °C for
16 hours in the dark and cooled to r.t. Then, the solvent was removed and extracted with
dichloromethane, washed with brine. The crude solid was purified by column
chromatograph to give the product as yellow solid (1746mg, 74% two-step yield). 1H
NMR (CDCl3, 500 MHz): δ 11.52 (s, 1H), 8.91 (d, J = 8.5 Hz, 2H), 8.54 (d, J = 8.5 Hz,
2H), 7.70~7.64 (m, 4H), 5.73 (s, 2H).

TBSO

CHO

10-((tert-butyldimethylsilyloxy)methyl)anthracene-9-carbaldehyde (2-6).
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Compound 2-5 (120 mg, 0.51mmol), TBSCl (100 mg, 0.66mmol), and imidazole (50 mg,
0.74mmol) were dissolved in 5mL of anhydrous DMF and stirred at r.t. for 14 hours.
After solvent removal under reduced pressure, the residue was dissolved in 20 mL of
ethyl acetate. It was then washed with 7 mL of water, 7 mL of 0.5N of hydrochloric acid,
and 7 mL of saturated brine. The organic layer was separated, dried over anhydrous
MgSO4, and then evaporated to give a yellow solid. The crude product was purified by
silica gel chromatography using ethyl acetate to hexane 1/50 as the eluent to give 2-6 as a
yellow solid (125mg, 70% yield). 1H NMR (CDCl3, 500 MHz): δ 11.51 (s, 1H), 8.91 (d, J
= 9 Hz, 2H), 8.50 (d, J = 9 Hz, 2H), 7.68~7.59 (m, 4H), 5.67 (s, 2H), 0.90 (s, 9H), 0.14 (s,
6H).

TBSO

NH

1-(10-((tert-butyldimethylsilyloxy)methyl)anthracen-9-yl)-N-methylmethanamine
(2-7).
Compound 2-6 (200 mg, 0.57mmol) was dissolved in 10mL of 2.0 M solution of
methylamine in methanol and the resulting mixture was stirred at r.t. for 6 hours. Then,
NaBH4 (65 mg, 1.71mmol) was added and the reaction mixture was stirred at r.t. for
another 2 hours. The solvent was removed under reduced pressure and the residue was
dissolved in ethyl acetate, the organic layer was washed with saturated NaHCO3 solution
and dried over anhydrous Na2SO4, Solvent evaporation gave a yellow solid which was
used in the following reaction without further purification.
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TBSO

N

Boc

tert-Butyl(10-((tert-butyldimethylsilyloxy)methyl)anthracen-9yl)methyl(methyl)carbamate (2-8).
To a solution of compound 2-7 (208 mg, 0.57 mmol) in 15 mL of anhydrous ethanol at r.t
was added di-tert-butyl dicarbonate (224 mg, 1.0 mmol). After stirring for 5 hours, the
solvent was removed under reduced pressure. Then, the reaction mixture was diluted with
dichloromethane, washed with brine and the organic layer was dried over Na 2SO4. The
solvent was removed to give yellow solids which were purified on the silica gel column
to afford compound 2-8 as yellow solids (265 mg, 96% two-step yield). 1H NMR (CDCl3,
500 MHz): δ 8.48~8.44 (m, 4H), 7.58~7.54 (m, 4H), 5.67 (s, 2H), 5.54 (s, 2H), 2.49 (s,
3H), 1.56 (s, 9H), 0.93 (s, 9H), 0.14 (s, 6H).

HO

N

Boc

Tert-Butyl (10-(hydroxymethyl)anthracen-9-yl)methyl(methyl)carbamate (2-9).
Compound 2-8 (540mg, 1.16mmol) was dissolved in THF, TBAF (450 mg, 1.72mmol)
was added to the solution in one portion. The mixture turned red immediately and then
became lighter. It was stirred for 1 hour and then the solvent was removed under reduced
pressure. The residue was dissolved in ethyl acetate, and washed with brine. The organic
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layer was evaporated under reduced pressure and dried over anhydrous Na2SO4 to give
off a red liquid which was purified by silica gel chromatography using ethyl acetate to
hexane 1 to 20 as eluent to give compound 2-9 as yellow liquid (407mg, quantitative
yield). 1H NMR (CDCl3, 300 MHz): δ 8.48~8.45 (m, 2H), 8.34 (m, 2H), 7.57 ~ 7.48 (m,
4H), 5.65 (s, 2H), 5.31 (s, 2H), 2.41 (s, 3H), 1.54 (s, 9H).

MsO

N

Boc

(10-((tert-butoxycarbonyl(methyl)amino)

methyl)

anthracen-9-yl)

methyl

methanesulfonate (2-10).
To a stirred mixture of compound 2-9 (180 mg, 0.51mmol) in 60 mL of dichloromethane,
methanesulfonyl chloride (114 mg, 1.0mmol) was added at 0 °C. Then, triethylamine
(126 mg, 1.25 mmol) was added and the resulting mixture was stirred at r.t. for 90 min.
After the reaction was complete, the solvent was removed under reduced pressure and
dissolved in dichloromethane. The organic layer was washed with brine and dried over
anhydrous Na2SO4. After solvent evaporation, the residue was collected and used in the
following step without further purification.

N
N
N

N

Boc
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Tert-butyl(10-((bis(pyridin-2-ylmethyl)amino)methyl)anthracen-9-yl)
methyl(methyl)carbamate(2-11).
To a solution of compound 2-10 (220 mg, 0.51 mmol) in 17 mL of acetonitrile was added
2,2‟-dicopicolyamine (111 mg, 0.56 mmol). It was refluxed for 40 hours. Then, the
solvent was removed under reduced pressure, residue was dissolved in dichloromethane.
The organic layer was washed with brine, dried over anhydrous Na2SO4. After solvent
evaporation,

the

residue

was

purified

by

silica

gel

chromatograph

using

dicholoromethane to methanol 50 to 1 as eluent to give compound 2-11 (220mg, 81%
two-step yield) as yellow solid. 1H NMR (CDCl3, 300 MHz): δ 8.50~8.39 (m, 4H),
8.39~8.36 (m, 2H), 7.60~7.44 (m, 6H), 7.30~7.33 (m, 2H), 7.13~7.11 (m, 2H), 5.47 (s,
2H), 4.70 (s, 2H), 3.90 (s, 4H), 2.44 (s, 3H), 1.55 (s, 9H).

N
N
N

NH

1-(10-((methylamino)methyl)anthracen-9-yl)-N,N-bis(pyridin-2ylmethyl)methanamine (2-12).
Compound 2-11 (220 mg, 0.41mmol) was dissolved in a solution of 2.5 mL of
dichloromethane and 0.6 mL of TFA. After stirred at r.t. for 0.5 hour until no compound
2-11 remained monitored by TLC, the solvent was removed under reduced pressure, and
the residue was dissolved in dichloromethane, extracted with dichloromethane/saturated
NaHCO3, and washed with brine. The solvent was then removed to produce a yellow
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liquid which was used in the next step without further purification. 1H NMR (CDCl3, 300
MHz): δ 8.49~8.45 (m, 4H), 8.34~8.31 (m, 2H), 7.60~7.43 (m, 6H), 7.31~7.29 (m, 2H),
7.11~7.08(m, 2H), 4.68 (s, 2H), 4.65 (s, 2H), 3.87 (s, 4H), 2.66 (s, 3H).

N
N
N

N
HO B
OH

2-((((10-((bis(pyridin-2-ylmethyl)amino)methyl)anthracen-9-yl)methyl)

(methyl)

amino ) methyl) phenylboronic acid (2-13).
To a solution of compound 2-12 (60 mg, 0.138 mmol) in 2 mL of THF was added K2CO3
(19

mg,

0.138

mmol)

and

2,2-dimethylpropane-1,3-diyl(o-

(bromomethyl)phenyl)boronate (44mg, 0.156mmol). The reaction mixture was refluxed
for 39 hours. After solvent removal under reduced pressure, it was dissolved in CH 2Cl2
and washed with brine. The organic layer was then collected. After solvent evaporation,
the residue was purified on silica gel chromatograph to give compound 2-13 (24mg, 27%
two-step yield) as yellow solid. 1H NMR (CD3OD-d4, 500 MHz): δ 8.46 (d, J=8.5 Hz,
2H), 8.31 (d, J=4 Hz, 2H), 8.09 (d, J=7.5 Hz, 2H), 7.66 (d, J= 7 Hz, 1H), 7.60~7.57 (m,
2H), 7.53~7.50 (m, 4H), 7.36~7.24 (m, 5H), 7.16 (m, 2H).

13

C NMR (CD3OD-d4, 500

MHz): δ 160.25, 149.13, 138.26, 135.34, 134.27, 132.43, 132.28, 131.78, 128.98, 127.84,
127.06, 126.70, 125.40, 125.17, 123.70, 64.21, 61.48, 52.21, 50.08, 40.14.
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N
N Zn
N

N
HO B
OH

2-((((10-((Bis(pyridin-2-ylmethyl)amino)methyl)anthracen-9-yl)methyl)

(methyl)

amino ) methyl) phenylboronic acid Zn complex (2-1).
To a solution of compound 2-13 (21 mg, 0.038 mmol) in 1mL of THF was added
Zn(NO3)2 (7 mg, 0.038 mmol), and the mixture was stirred for 30 min at r.t. After
concentration in vacuo, the residue was dissolved in HPLC acetonitrile and purified by
reverse phase HPLC to get compound 2-1 as yellow solid (24 mg, quantitative yield).
ESI-MS: [M+H-Zn] Calculated for C36H35BN4O2: 567.29, found 567.29.

Control 2-2 was synthesized following the procedures in Scheme 2.4.

N
N
N

N

N-Benzyl-1-(10-((bis(pyridin-2-ylmethyl)amino)methyl)anthracen-9-yl)-Nmethylmethanamine (2-14).
To a solution of compound 2-12 (19 mg, 0.044mmol) in 1.5 mL of THF was added
K2CO3 (10 mg, 0.072mmol). The reaction mixture was refluxed for 39 hours. After
solvent removal under reduced pressure, it was dissolved in CH 2Cl2 and washed with
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brine. The organic layer was then collected. After solvent evaporation, the residue was
purified on silica gel chromatograph using CH2Cl2 to methanol 20 to 1 as eluent to give
compound 2-14 (14mg, 61% yield) as yellow solid. 1H NMR (CDCl3, 300 MHz): δ
8.49~8.41 (m, 5H), 7.59~7.53 (m, 2H), 7.48~7.42 (m, 4H), 7.33~7.25 (m, 8H), 7.11~7.07
(m, 2H), 4.68 (s, 2H), 4.46 (s, 2H), 3.66 (s, 4H), 3.67(s, 2H), 2.21 (s, 3H).

13

C NMR

(CDCl3, 300 MHz): δ 159.68, 148.67, 139.39, 136.15, 131.22, 129.16, 128.11, 126.98,
125.62, 125.52, 124.97, 123.56, 121.93, 62.40, 60.57, 53.66, 51.07, 42.15.

N
N Zn
N

N

N-benzyl-1-(10-((bis(pyridin-2-ylmethyl)amino)methyl)anthracen-9-yl)-Nmethylmethanamine Zn complex (2-2).
To a solution of compound 2-14 (14 mg, 0.027mmol) in 1 mL of THF was added
Zn(NO3)2 (5 mg, 0.027 mmol), and the mixture was stirred for 30 min at r.t. After
concentration in vacuo, the residue was dissolved in HPLC acetonitrile and purified by
reverse phase HPLC to get compound 2-2 (16 mg, quantitative yield) as yellow solid.
ESI-MS: [M+H-Zn] Calculated for C36H34N4: 523.28, found 523.28.

Control Compound 2-3 was synthesized following the procedures in Scheme 2.5.
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HO

NH

(10-((methylamino) methyl) anthracen-9-yl) methanol (2-15).
Compound 2-5 (53 mg, 0.22 mmol) was dissolved in 2mL of 33% wt methylamine in
ethanol, and the resulting mixture was stirred at r.t. for 6 hours. Then, NaBH 4 (73 mg,
1.92 mmol) was added and the reaction mixture was stirred at r.t. for another 2 hours. The
solvent was removed under reduced pressure and the residue was dissolved in ethyl
acetate, the organic layer was washed with water and dried over anhydrous Na 2SO4,
Solvent evaporation gave a yellow solid which was used in the following steps without
further purification.

HO

N
HO B
OH

2-((((10-(hydroxymethyl)

anthracene-9-yl)

methyl)

(methyl)

amino)

methyl)

phenylboronic acid (2-3).
To a solution of compound 2-15 (60 mg, 0.239mmol) in 7 mL of THF was added K2CO3
(52

mg,

0.377

mmol)

and

2,2-dimethylpropane-1,3-diyl

(o-

(bromomethyl)phenyl)boronate (44 mg, 0.155 mmol). The reaction mixture was refluxed
for 39 hours. After solvent removal under reduced pressure, it was dissolved in CH 2Cl2
and washed with brine. The organic layer was then collected. After solvent evaporation,
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the residue was purified on silica gel chromatograph to give compound 2-3 as yellow
solid (35% two-step yield). 1H NMR (CD3OD-d4, 500 MHz): δ 8.57 (d, J=9 Hz, 2H),
8.24 (d, J=8.5 Hz, 2H), 7.70 (d, J= 7.5 Hz, 1H), 7.63~7.56 (m, 4H), 7.41~7.35 (m, 2H),
7.28~7.25 (m, 1H), 5.62 (s,2H), 5.14 (s,2H), 4.46 (s, 2H), 2.43 (s, 3H).

13

C NMR

(CD3OD-d4, 500 MHz): δ 135.39, 132.87, 131.83, 131.46, 131.06, 129.04, 128.03,
127.62, 126.99, 126.58, 125.44, 114.06, 64.26, 57.19, 50.02, 40.01. ESI-MS: [M+H-H2O]
Calculated for C24H23BNO2: 368.18, found 368.18.

Spectroscopic materials and methods:
Millipore water was used to prepare all aqueous solutions. The pH was recorded by a
Beckman ΦTM 240 pH meter. Fluorescence emission spectra were obtained on a
Shimadzu RF-5301PC spectrofluorophotometer. 10 mM probe 2-1 in MeCN was
prepared as the stock solution, 5 µL of the stock solution was added to 4995 µL 10mM
PH=7.2 HEPES buffer to make the final concentration of 10 µM. All the analytes (ATP,
ADP, AMP, Na4P2O7, K3PO4 and mannose) were prepared by dissolving the respective
amount in water to make the final concentration of 10 µM. Fluorescence spectra were
measured 3 min after the addition of each analyte.

Preparation of cell cultures
SH-SY5Y cell line was purchased from American Type Culture Collection. The cells
were cultured in DMEM containing 10% FBS and 1% (v/v) antibiotic-antimycotic
solution at 37C with 95% air/5% CO2 in an incubator.
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Intracellular fluorescence imaging
Grow SH-SY5Y cells on coverslips inside a dish filled with DMEM culture medium.
When cells reached the 70 % confluency, removed the media from the dish and added
pre-warmed (37°C) staining solution containing ATP probe 2-1 (10 µM) and incubated
for 30 min under growth conditions. Following a through wash, the coverslips were
placed onto Olympus IX71 fluorescence microscopy and imaged with DAPI dichroic
mirrors. Cells pretreated with 0.1mM KCN (inhibitor of ATP) before probe addition was
used as a negative control. The images of control compound 2-2 and 2-3 stained cells
were collected as another negative control.
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Chapter 3
Development of Photo-triggered Anticancer Prodrug to Release
Multiple Drugs

3.1 Background
Prodrug strategy is an effective method in drug discovery, especially for the
anticancer drugs

[1]

. It not only improves ADME (absorption, distribution, metabolism,

excretion), but also greatly alleviates systematic toxicity and significantly enhances
therapeutic index with controlled release of active drugs at the site of action

[2]

. Recently,

multidrug delivery systems (MDDSs) have been developed with the advances in
nanobiotechnology and material science. Multidrug delivery systems (MDDSs) allow
multiple drug moieties to be delivered to be released at the preferred site. Compared with
monochemotherapy, the combination therapy has brought about synergistic effect and
lowered side effects so that they are commonly used in clinical chemotherapy [3]. Despite
significant progress in this field, very few small molecule based multiple anticancer drug
release systems are developed. The Smyth and coworker made a prodrug with a
cephalosporin nucleus, upon hydrolysis by β-lactamase, releases aminoglutethimide (an
aromatase inhibitor) and coumate (a sulfatase inhibitor) to inhibit estrogen production in
hormone-dependent breast cancer[4]. With the limited achievements in this field, we hope
to expand the horizon of this field by developing new strategies to release multiple drugs
in cancer chemotherapy.
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As well documented, DNA alkylating agents are one of the most widely used
chemotherapeutic agents

[5-6]

. However, their high degree of reactivity accompanies high

systematic toxicity that often prevents their clinical applications. To overcome severe
side effect and improve therapeutic efficiency, prodrug strategy has been widely used to
mask the highly reactive DNA alkylating agents

[7]

. Among various prodrug activation

triggers, light is a highly orthogonal external stimulus, precise control of drug release at
specific time and location can be realized

[8-17]

. Currently, no report was made on

prodrugs that release multiple DNA alkylating agents upon activation. Thus, we have
designed, synthesized and characterized a light activated prodrug 3-1 that releases two
different types of chemotherapeutic agents – nitrogen mustard type mechlorethamine and
quinone methide type o-quinone methide anticancer drug.

3.2 Design Strategy
As reported, biphenol biquaternary ammonium demonstrated very potent ISC
properties upon photoactivation. Its extraordinary ISC activity is induced by its strong
interaction with the backbone of double-stranded DNA, upon photoactivation, the
subsequent formation of o-quinone methide intermediate easily forms intercross links
with DNA double strand

[10, 18]

. Inspired by the previous report, we took biphenol

biquaternary ammonium as the prodrug nucleus structure. The two phenol groups were
masked by 1-(2-nitrophenyl)ethyl (NPE) photo-trigger, and DNA cross-linking agent
mechlorethamine was inactivated at the phenol ortho position by converting to a charged
nitrogen atom (Scheme 3.1).
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The prodrug 3-1 was expected to be inactive as both the toxicity of o-quinone mthide
and mechlorethamine was significantly reduced in the prodrug form. On the one hand, oquinone methide was not formed until activated by light. On the other hand, the positive
charge developed on the nitrogen decreases the electron density of mechlorethamine
required for DNA alkylation. Upon photoactivation, NPE group was unmasked from the
phenol, and o-quinone methide was formed subsequently, meanwhile, two molecules of
mechlorethamine were released. Two types of DNA alkylating agents collectively react
with DNA double strand to form ISC, inhibiting DNA separation during DNA replication
and transcription, consequently leading to cell death. The photo-controlled activation is
expected to control the dosage of drug released in a spatial and temperol manner.

Scheme 3.1 Design of photo-triggered prodrug for multiple drug release.
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3.3 Synthesis
The biphenol biquaternary ammonium prodrug 3-1 was synthesized according to the
procedure shown in Scheme 3.2. Compound 3-9 was obtained by Duff Reaction. Lithium
aluminum hydride reduction gave compound 3-10 in quantitative yield. Under the K2CO3
basic condition, the photo sensitive group 1-(bromomethyl)-2-nitrobenzene was
selectively coupled at the phenolic position to yield compound 3-11 which was then
converted to 3-12 using tribromophosphine. Treatment of 3-12 with excess amount of Nmethyldiethanolamine under reflux condition gave compound 3-13, which was then
converted to the target product 3-1 by thionyl chloride.

Scheme 3.2 Synthetic routes for prodrug 3-1

Scheme

3.2

Synthetic

routes

for

prodrug

3-1.

Reagents

and

conditions:

(a).

hexamethylenetetraamine, TFA, 80 °C, 3 h. (b). LiAlH4, THF, 1.5 h. (c). 1-(bromomethyl)-2-

62

nitrobenzene, K2CO3, MeCN, 50°C, 4.5 h. (d). PBr3, DCM, in dark, -5 °C to -3 °C, 70 min. (e).
2,2'-(methylazanediyl)diethanol, anhydrous MeCN, in dark, 85°C ,12 h. (f). SOCl2, 3 d.

3.4 Photo-triggered Drug Release Studies
After obtaining prodrug 3-1, we performed photo-triggered drug release studies.
According to the proposed activation mechanism (Scheme 3.1), both the o-quinone
methide 3-4 and mechlorethamine 3-5 can be released upon photoactivation.
In the presence of UV light, NPE group on prodrug 3-1 can be cleaved to form phenol
biquaternary ammonium in aqueous solutions. According to Freccero and Zhou‟s reports
[10-12, 18-19]

, phenol processing a quaternary ammonium group forms o-quinone methide by

photoactivation in aqueous solutions. Thus, prodrug 3-1 should be able to release oquinone methide 3-4. However, o-quinone methide 3-4 is a very unstable intermediate
that cannot be easily monitored or isolated. To prove the formation of o-QM 3-4, DNA
alkylating tests will be performed in the following section.
Meanwhile, mechlorethamine 3-3 is not easily isolated and characterized for its high
reactivity and lack of UV-vis absorption. To monitor the existence of mechlorethamine 31, we used diethyldithiocarbamate (DDC) to rapidly trap drug 3-5, and monitored the UV
absorption of the stable bisadduct 3-9[20] (Scheme 3.3). Comparing with the standard
compound 3-9, the presence of 3-5 was confirmed by RP-HPLC.
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Scheme 3.3 Chemistry of detection of mechlorethamine

3.5 Kinetic Studies
Next, we conducted the more detailed kinetic studies of the photolytic reaction of
prodrug 3-1 by monitoring the consumption of prodrug 3-1 as well as the formation of
mechlorethamine 3-3 using RP-HPLC. An aqueous solution of 2 mM prodrug 3-1 was
irradiated under UV light (2 W, 365 nm) for different time courses. We observed a
decreasing peak 24.7 min corresponding to the decomposition of prodrug 3-1 (Figure
3.1a). To capture the UV-vis inactive compound 3-5, the irradiated solution was
incubated with 27.5 mM DDC at 37℃ for 20 min to complete the trapping reaction.
HPLC analysis confirmed the presence of 3-5 by comparing with the standard peak of
compound 3-9 at 20.3 min retention time under the same RP-HPLC condition, by
monitoring the concentration of bisadduct 3-9 peak at 20.3 min, the amount of 3-5 can be
calculated. Through path A: direct substitution reaction with prodrug 3-1, there is roughly
a constant concentration of 3-9 under all conditions for 20 min incubation time with DDC.
The actual amount of bisadduct 3-9 released from the photolytic reaction (path B) can be
obtained by subtracting 3-9 produced from path A from the total amount detected
(Scheme 3.4). Using the standard curve of compound 3-9, the conversion percentage was
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plotted against time of UV irradiation. The amount of mechlorethamine released was
proportional to the time of UV irradiation.
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Figure 3.1. (a). Controlled decomposition of prodrug 3-1 in aqueous solution upon UV
irradiation for designated time courses monitored by RP-HPLC. (b). Controlled release of
mechlorethamine 3-5 in aqueous solution upon UV irradiation for designated time courses
monitored by RP-HPLC.
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Scheme 3.4 Chemistry of detection of mechlorethamine release from prodrug 3-1 by: (path A)
direct substitution with diethyldithiocarbamate (DDC) and (path B) photolytic fragmentation.

3.6 Cell Viability Test
Before conducting cellular tests, we firstly evaluated the stability and cell
permeability of prodrug 3-1. Concerning the fact that prodrug 3-1 is an electrophile, we
tested its stability in a thiol rich cellular environment. As reported, GSH is present at very
high levels in the cytosol, comprising about 90% of nonprotein sulfur with 1-2mM
concentrations in most of cells [21]. An aqueous solution containing 10 mM prodrug 3-1
was incubated with 2 mM GSH for 6 hours at 37 ℃, DDC was incubated for 20 min to
trap the released active drug 3-5. An aliquot of solution was injected to RP-HPLC. We
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have not observed decomposition of prodrug 3-1 nor increased amount of active drug 3-4,
which showed that prodrug 3-1 was very stable in a GSH rich cellular environment.
To evaluate the cell permeability of prodrug 3-1, 0.5 mM prodrug 3-1 was incubated
with HeLa cells for 2 hours, cell lysate was collected. After filtration, it was injected into
RP-HPLC, a single peak on HPLC, i.e. the prodrug 3-1 peak was detected. It indicated
that prodrug 3-1 was cell permeable.
Having established that prodrug 3-1 is able to release active mechlorethamine and
showed high potency in inducing DNA cross-links. We evaluated its ability in inhibiting
cancer cell growth as well as its cytotoxicity towards normal cells.
To begin with, cytotoxicity of prodrug 3-1 was evaluated on normal skin cells (Hekn
cell lines) by using cell counting kit-8 (CCK-8). As is shown in Figure 3.2, without UV

exposure on Hekn cells, inactivated prodrug 3-1 showed negligible cytotoxicity towards
normal skin cells. Even with a drug concentration as high as 0.5 mM, Hekn cell viability
as high as 89.2% was observed. After 30 min UV exposure, activated prodrug 3-1
showed lower cell viability than inactivated prodrug under the same concentration with
majority of the cells survived. Thus, prodrug 3-1 displays low systematic toxicity towards
normal cells both with and without UV activation. Its low toxicity assures its potential for
further study.
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Figure 3.2. Cell viability assays of prodrug 3-1 on normal skin cells (Hekn cell lines) Prodrug 3-1
was incubated with the cells for 2 h followed by 30 min UV irradiation. The cell viability was
measured after 24 h incubation using cell counting kit-8 (CCK-8).

Next, we evaluated prodrug 3-1 ability in inhibiting cancer cell growth. In the
presence of 30 min mild UV irradiation (low-power UV light as light source was used
and positioned 75 cm away from the reaction), with an increasing drug concentration, a
larger amount of cancer cells (HeLa cells) was killed. In the absence of UV activation,
prodrug 3-1 showed very limited cytotoxicity towards HeLa cells (Figure 3.3).
Meanwhile, we have observed an impressive selectivity towards cancer cells. This is
important in practical application. With a drug dosage of 0.5 mM and UV irradiation
selectively at the tumor site, 2.1% cell viability on HeLa cells compared with 89.1% cell
viability on Hekn cells. This might be explained by the selective activation of prodrug 31 with UV light as well as the ICL property of the inhibition mechanism. Cancer cells
generally grow and divide at a much faster rate than normal cells. It is expected that
much higher DNA replication and transcription activities take place in cancer cells than
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those in normal cells, thus cell growth inhibition by intercross links formation is much
more efficient towards cancer cells.

cell viability
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Figure 3.3. Cell viability assays of prodrug 3-1 on cancer cells (HeLa cell lines) Prodrug 3-1 was
incubated with the cells for 2 h followed by 30 min UV irradiation. The cell viability was
measured after 24 h incubation using cell counting kit-8 (CCK-8).

To prove that the anticancer properties of prodrug 3-1 was due to the release of both
mechlorethamine 3-5 and o-quinone methide 3-4, we made control compound 3-13 which
only releases o-qionone methide 3-4 upon UV irradiation. Prodrug 3-1 exhibited much
more significant potency than control compound 3-13. At 0.5 mM concentration, prodrug
3-1 demonstrated 2.1% cell viability comparing to compound 3-13 with 60.6% cell
viability. In the absence of UV, control 3-13 is less cytotoxic than prodrug 3-1. The
above results demonstrated that the incorporating mechlorethamine into the prodrug
scaffold greatly improved drug potency.
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Figure 3.4. Cell viability assays of prodrug 3-1 and control compound 3-13 on cancer cells
(HeLa cell lines) Prodrug 3-1 and control compound 3-13 were incubated with the cells for 2 h
followed by 30 min UV irradiation. The cell viability was measured after 24 h incubation using
cell counting kit-8 (CCK-8).

3.7 Summary
In conclusion, we have developed a photo-triggered multiple drug delivery system for
anticancer drug releasing. The release of both of the active DNA alkylator o-quinone
methide and mechlorethamine can be controlled with UV irradiation. We carried out
detailed kinetic studies by monitoring the consumption of prodrug 3-1 and releasing of
active mechlorethamine. From the cell viability tests, prodrug 3-1 showed negligible
cytotoxicity towards normal skin cells (Hekn cells) with and without UV activation.
Morever, activated prodrug 3-1 showed potent anticancer activity towards cancer cells.
By comparing the results with control compound 3-13, it showed that the anticancer
activity of prodrug 3-1 was mainly contributed by the release of mechlorethamine. The
preliminary results of multiple drug delivery system based on biphenol biquaternary

70

ammonium nucleus structure may serve as a potential prodrug candidate as
chemotherapeutic agent.

3.8 Experimental Section
General Information
All reactions were carried out in dried flasks. The reactions were monitored by TLC
for completion. Commercially available reagents were used as received without further
purification unless otherwise specified. Merck 60 silica gel was used for column
chromatography, and Whatman silica gel plates with fluorescence F254 were used for
thin-layer chromatography (TLC) analysis.

1

H and

13

C NMR spectra were recorded on

Bruker Avance 500 or 300. Data for 1H are reported as follows: chemical shift (ppm), and
multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet). Data for

13

C

NMR are reported as ppm. Mass Spectra were obtained from University of New Mexico
Mass Spectral facility.

Synthesis of prodrug 3-1
Compound 3-1 was synthesized following the procedures in Scheme 3.2

4,4'-dihydroxy-[1,1'-biphenyl]-3,3'-dicarbaldehyde (3-9)
4,4'-Biphenol (279 mg, 1.5 mmol) and hexamethylenetetraamine (472 mg, 3.37 mmol)
were dissolved under argon in 5mL of anhydrous TFA, and stirred for 3 hours at 80 ℃, a
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yellow solution was formed. After cooling to room temperature, the solution was poured
into 4N HCl and stirred for 2 hours, during this time solids were formed. The yellow
solids were collected by filtration, washed with water (2×) and cold ethanol once, and
dried in vaccum. Purification by column chromatography (silica gel) gave product as
yellow solids (363 mg, 86% yield). 1H NMR (CDCl3 with one drop of CD3OD , 300
MHz): δ 9.97 (s, 2H), 7.71 (m, 4H), 7.07 (d, J = 9.3 Hz, 2H).

3,3'-bis(hydroxymethyl)-[1,1'-biphenyl]-4,4'-diol (3-10)
4,4'-Dihydroxy-[1,1'-biphenyl]-3,3'-dicarbaldehyde (121 mg, 0.5 mmol) was dissolved in
10 mL of dry THF, 2 eq LiAlH4 (38 mg, 1 mmol) was added in portions over 30 min at
0 °C while stiring, the solution was slowly warmed up to room temperature and stirred for
another 1 hour until the reaction was complete. After solvent removol, the residue was
redissolved in 2N HCl, then it was extracted with ethyl acetate and 2N HCl, the organic
layer was obtained. After solvent evaporation, yellow solids were obtained as desired
product (123 mg, quantitative yield). 1H NMR (CD3OD, 500 MHz): δ 7.48 (s, 2H), 7.29
(d, J = 8.0 Hz, 2H), 6.80 (d, J = 8.0 Hz, 1H), 4.69 (s, 4H), 13C NMR (CD3OD, 500 MHz):
δ 155.09, 133.91, 128.68, 127.35, 127.26, 166.20, 61.16.
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(4,4'-bis((2-nitrobenzyl)oxy)-[1,1'-biphenyl]-3,3'-diyl)dimethanol (3-11)
Potassium carbonate (22 mg, 0.161 mmol) was dissolved in 1 mL of acetonitrile,
followed by the addition of 1 eq 3,3'-bis(hydroxymethyl)-[1,1'-biphenyl]-4,4'-diol (18mg,
0.073mmol) and 2.2 eq 1-(bromomethyl)-2-nitrobenzene (35mg, 0.161mmol). The
reaction mixture was stirred in dark at 50 °C for 4.5 h. After solvent removal under
reduced pressure, the crude product was further purified by silica column
chromatography to give yellow solids as product (24 mg, 68% yield). 1H NMR (acetoned6, 300 MHz): δ 8.16 (d, J = 8.4 Hz, 2H), 7.95 (d, J = 7.5 Hz, 2H), 7.81 (m, 4H), 7.64 (m,
2H), 7.47 (dd, J1 = 8.4 Hz, J1 = 2.4 Hz, 2H), 7.08 (d, J = 8.4 Hz, 2H), 5.57 (s, 4H), 4.80
(d, J = 5.7 Hz, 4H), 4.16 (t, J = 5.7 Hz, 2H). m.p.:239-240 °C.
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3,3'-bis(bromomethyl)-4,4'-bis((2-nitrobenzyl)oxy)-1,1'-biphenyl (3-12)
A solution of tribromophosphine (643 mg, 226 μL, 2.3 eq mmol) in 2.0 mL of anhydrous
dichloromethane was added dropwise to a solution of 8(4,4'-bis((2-nitrobenzyl)oxy)[1,1'-biphenyl]-3,3'-diyl)dimethanol (654 mg, 1 eq mmol) in 10 mL of anhydrous
dichloromethane over 30 min with the temperature between -5 °C and -3 °C. The
reaction mixture was stirred in dark at rt for 40 min. After the reaction is complete, it was
washed with brine, concentrated and run column to give light yellow solids as product
(56% yield). 1H NMR (DMSO-d6, 300 MHz): δ 8.17 (dd, J = 8.1 Hz, 2H), 7.93 (d, J =
6.6 Hz, 2H), 7.82 (m, 2H), 7.76 (d, J = 2.4 Hz, 2H), 7.62 (m, 4H), 7.16 (d, J = 9 Hz, 2H),
5.61 (s, 4H), 4.76 (s, 4H). m.p.: 216-219 °C.

N,N'-((4,4'-bis((2-nitrobenzyl)oxy)-[1,1'-biphenyl]-3,3'-diyl)bis(methylene))bis(2hydroxy-N-(2-hydroxyethyl)-N-methylethanaminium) bromide (3-13)
A solution of 3,3'-bis(bromomethyl)-4,4'-bis((2-nitrobenzyl)oxy)-1,1'-biphenyl (389 mg,
1.0 mmol) and 2,2'-(methylazanediyl)diethanol (357 mg, 8.0 mmol) in 10 mL of
anhydrous acetonitrile was stirred in dark at 85°C for 12 h. After filtration, white solid
was obtained as product (76% yield). 1H NMR (DMSO-d6, 500 MHz): 8.20 (d, J = 8.5
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Hz, 2H), 7.91 (s, 2H), 7.83 (m, 6H), 7.67 (m, 2H), δ 7.32 (d, J = 9.0 Hz, 2H), 5.62 (s,
4H), 5.31 (m, 4H), 4.75 (s, 4H), 3.88 (m, 8H), 3.59 (m, 4H), 3.42 (m, 4H), 3.02 (m, 6H).
m.p.: 212-215°C.

N,N'-((4,4'-bis((2-nitrobenzyl)oxy)-[1,1'-biphenyl]-3,3'-diyl)bis(methylene))bis(2chloro-N-(2-chloroethyl)-N-methylethanaminium) chloride (3-14)
N,N'-((4,4'-bis((2-nitrobenzyl)oxy)-[1,1'-biphenyl]-3,3'-diyl)bis(methylene))bis(2hydroxy-N-(2-hydroxyethyl)-N-methylethanaminium) bromide (43 mg, 0.05 mmol) was
dissolved in 2 mL of thionyl chloride. The reaction mixture was stirred at rt for 3 d.
After solvent evaporation under reduced pressure, white solid was obtained as product
(quantitative yield). m.p.: 118-120 °C.

(Methylazanediyl)bis(ethane-2,1-diyl) bis(diethylcarbamodithioate) (3-9)
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1

H NMR (CDCl3, 500 MHz): δ 4.03 (m, 4H), 3.75 (m, 4H), 3.46 (t, J = 11.5 Hz, 4H),

2.79 (t, J = 12.0 Hz, 4H), 2.42 (s, 3H), 1.28 (m, 12H),

13

C NMR (CDCl3, 500 MHz): δ

55.75, 49.47, 46.65, 34.59, 12.46, 11.58.

HPLC monitoring of drug release
Prodrug 3-1 (2 mM) was dissolved in an aqueous solution of pH 7.4 HEPES buffer (30%
DMSO), a hand-held UV lamp (365 nm, 2W) was positioned 10 cm away from the
reaction vial as light source. After designated reaction time, an aliquot of 200 μL
solution was taken and incubated with 20 μL 27.5 mM DDC at 37 °C for 20 min to allow
complete reaction. Next, an aliquot of 20 μL solution was submitted to RP-HPLC to be
analyzed by a 254 nm UV detector, the amount was integrated by the area under each
peak, and calculated from the standard curves under the same HPLC condition.
HPLC condition: Eclipse XDB-C8 column, flow rate is 0.8 mL/min, 0-20 min:
MeCN/H2O (10:90), 20-40 min: MeCN/H2O (30:70).

Cell viability test
Cell viability was measured by using cell counting kit-8 (CCK-8), which
quantitatively measures activities of dehydrogenases in cells. Cells (5  103 cells/well)
were seeded into 96-well microtiter plates. Following treatment with prodrug 4-1 and
different reaction conditions (in the presence or absence of 365 nm UV light), 10 μL of
CCK-8 solution was added to each well of the plate. The plate was placed into the
incubator at 37 C with 95% air/5% CO2. After one hour incubation, the absorbance was
measured at 450 nm in a Bio-Rad 3350 microplate reader. Cells without any treatment
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were used as 100% cell viability. The cell viability was calculated by using the formula:
Cell viability = (Experimental absorbance value – culture medium absorbance
value)/(without treatment absorbance value – culture medium absorbance value).
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Chapter 4
Development of Multi-functional Photo-triggered Fluorescent
Prodrug for Imaging and Drug Release

4.1 Background
Despite the fact that nitrogen mustards such as mechlorethamine and chlorambcil are
the earliest and perhaps most extensively studied of the DNA interstrand cross-linking
agents, nowadays they still are the front line therapies for the treatment of many types of
human cancers in clinics and provide an area of extremely intense and progressive
investigation [1-3]. However, their applications are severely limited due to high systemic
toxicity as a result of their poor selectivity between normal and cancer cells. One of the
effective strategies to reduce toxicity towards normal cells is to transform inactive
prodrugs that can be activated to release preferentially at the site of action in tumor cells.
In this regard, significant efforts have been made on the development of stimuli, such as
light or heat

[4-13]

, hypoxia condition

[14-25]

, oxidative stress[26-31], and other means[2, 32-36]

to control release of the active DNA alkylating agents. Nevertheless, these methods
cannot spatiotemporally monitor the release event in order to reach the optimal
therapeutic effectiveness in high demanding personalized medicine.
The use of light as a remote-activation mechanism for drug delivery has received
considerable attention as a result of its capacity of highly specific spatial and temporal
control of drug release.[3] This feature renders the light-triggered theranostics particularly
attractive in personalized medicine.

Therefore, intensive efforts have been directed
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towards the development of photo-triggered theranostic agents including DNA
alkylators[37]. The studies in the field are mainly focused on the nanomaterial-based drug
delivery systems (DDSs)[12,

38-42]

. Despite impressive progress, to the best of our

knowledge, a small molecule-based photo-triggered DDS enabling to simultaneously
deliver and monitor drug release of DNA alkylating agents has not been reported [43-48]
because unlike nanomaterial, it is formidably challenging to incorporate an imaging tag, a
drug and a trigger into one small molecule. A new strategy that contributes to this
subject should be of broad interest. Herein we wish to disclose the first example of
photo-triggered fluorescent theranostic prodrug for controlled release and monitoring of
DNA alkylating agent mechlorethamine.

4.2 Design Strategy
In the design of a new nitrogen mustard photo-triggered prodrug, three important
criteria must be taken into consideration: (1) alleviate systemic toxicity and increase
tumor selectivity; (2) provide precise control of drug release; (3) monitor drug release
process using non-invasive, sensitive fluorescent imaging with desired „off-on‟ signal.
Therefore, a new prodrug 4-1 consisting of three essential components – a masked DNA
cross-linking agent mechlorethamine, a 1-(2-nitrophenyl)ethyl (NPE) photo-trigger, and a
coumarin fluorophore is designed (Scheme 4.1).
This prodrug is expected to act as an effective drug delivery system enabling
concurrently both controlled release and fluorescent-based drug monitoring.

It is

conceivable that the toxicity of mechlorethamine would be significantly reduced by the
positive charge developed on the nitrogen that strongly decreases the electron density of
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mechlorethamine required for alkylation. Moreover, the strong electron-withdrawing
moiety coupled with the second strong electron withdrawing NPE could effectively block
internal charge transfer (ICT), thereby leading to the prodrug 4-1 initially nonfluorescent.
However, upon photo-irradiation, the release of the active drug mechlorethamine
accompanies a desired „off-on‟ fluorescence signal by change from the „pull-pull‟ to a
„push-pull‟ system. In addition, the coumarin fluorophore not only acts as a signal tag,
but also as an antenna, greatly improve photolysis efficiency of NPE group by enhancing
UV absorbance and transferring energy to NPE group. Finally, the positively charged
prodrug 4-1 may also enhance the selectivity and binding affinity of negatively charged
DNA.

Scheme 4.1 Design of photo-triggered fluorescent prodrug for mechlorethamine.

4.3 Synthesis
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The synthetic route for prodrug 4-1 is outlined in Scheme 4-2. Starting from 2Methylresorcinol, 7-hydroxyl, 8-methyl coumarin 4-8 was made, which was then
protected as coumarin acetate, followed by bromination with NBS, and hydrolysis to
afford 7-hydroxyl-8-(hydroxymethyl) coumarin 4-11 in moderate yield. Under the mild
basic condition, the photo sensitive group 1-(bromomethyl)-2-nitrobenzene was
selectively coupled at the phenolic position to yield 8-(hydroxymethyl)-7-(2nitrobenzyloxy)-coumarin

4-12,

which

was

then

converted

to

4-13

using

tribromophosphine. Treatment of 4-13 with N-methyldiethanolamine yielded 4-14, which
was converted to target compound 4-1 using thionyl chloride.

Scheme 4.2 Synthetic routes for prodrug 4-1. Reagents and conditions: (a). concentrated H2SO4,
2-hydroxysuccinic acid, MW (240W, 120℃), 4 min; (b). acetic anhydride, pyridine, rt, 12 h; (c).
NBS, AIBN, CCl4, reflux, 6 h; (d). CaCO3, dioxane/H2O=1/1, 50 ℃, 24 h; (e). 1-(bromomethyl)2-nitrobenzene, K2CO3, MeCN, 50℃, in dark, 5h; (f). PBr3, DCM, rt, in dark, 70 min; (g). 2,2'(methylazanediyl)diethanol, dry MeCN, rt, in dark; (h). SOCl2, rt, in dark, 3 d.
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4.4 Photo-triggered Drug Release Studies
With the compound 4-1 in hand, firstly we performed photo-triggered drug release
studies. According to the proposed mechanism (Scheme 4.1), both the active drug 4-4
and fluorescent product 4-6 will be formed during the process. Compound 4-6 can be
easily monitored and isolated for its strong fluorescence and stability in aqueous solution,
while active drug 4-4 itself is not easily isolated and characterized due to its high
reactivity and lack of UV-vis absorption. According to the previous report

[49]

, we used

diethyldithiocarbamate (DDT) to rapidly trap drug 4-4, and monitor the UV absorption of
the stable bisadduct 4-15 (Scheme 4.3). Comparing with the standard compound 4-15,
the presence of 4-4 was confirmed by RP-HPLC.

Scheme 4.3 Chemistry of detection of mechlorethamine

An aqueous solution containing 5 mM prodrug 4-1 was prepared and irradiated with
a hand-held UV lamp (2 W, 365 nm).

Time course study revealed complete

disappearance of 4-1 in 90 min. A highly fluorescent presumed product was formed
during the process, monitored by a fluorometer. The fluorescent molecule was isolated
and characterized by 1H and

13

C NMR and mass spectroscopy. Its structure was
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determined to be compound 4-6. Meanwhile, the irradiated solution was incubated with
27.5 mM DDC at 37°C for 20 min, HPLC analysis confirmed the presence of 4-4 by
comparing with the standard peak of compound 4-15 at 20.3 min retention time under the
same (RP) HPLC condition.
The above studies proved the proposed reaction mechanism and working hypothesis.
Prodrug 4-1 was able to release and meanwhile monitor the release process by
fluorescence.

4.5 Kinetic Studies
Next, we conducted the more detailed kinetic studies of the photolytic reaction of
prodrug 4-1 with reversed-phase (RP) HPLC. The concentrations of prodrug 4-1,
photolytic products 4-15 and 4-4 were monitored. An aqueous solution of 2 mM prodrug
4-1 was irradiated under UV light (2 W, 365 nm) for different time courses. Then an
aliquot sample was taken and injected to (RP) HPLC using water/acetonitrile mixture as
mobile phase at a flow rate of 0.8 mL/min at λmax 254 nm. We observed the decreasing of
peak at 32.2 min accompanied with the concurrent appearance of new peak at 16.2 min.
Peak at 32.2 min corresponded to the decomposition of prodrug 4-1 (Figure 4.1a), while
the new peak resulted from the formation of photoproduct 4-6 (Figure 4.1b). The release
of fluorescent product 4-6 was proportional to the time of UV irradiation.
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Figure 4.1. (a). Controlled decomposition of prodrug 4-1 in aqueous solution upon UV
irradiation for designated time courses monitored by RP-HPLC. (b). Controlled release of
fluorescent molecule compound 4-6 in aqueous solution upon UV irradiation for designated time
courses monitored by RP-HPLC. (c). Controlled release of mechlorethamine 4-4 in aqueous
solution upon UV irradiation for designated time courses monitored by RP-HPLC.

To quantify the amount of active drug 4-4 released from the photolytic reaction, DDT
was used as a trapping agent. From the above reaction mixture, an aliquot sample was
taken and incubated with 27.5 mM DDC for 20 min at 37°C to complete the trapping
reaction. Then, it was injected into RP-HPLC, by monitoring the concentration of
bisadduct 4-15 peak at 20.3 min, the amount of 4-4 can be calculated. Through path A:
direct substitution reaction with prodrug 4-1, there is roughly a constant concentration of
4-15 under all conditions for 20 min incubation time with DDC. The actual amount of
bisadduct 4-15 released from the photolytic reaction (path B) can be obtained by
subtracting 4-15 produced from path A from the total amount detected (Scheme 4.4).
Using the standard curve of compound 4-15, the conversion percentage was plotted
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against time of UV irradiation. The amount of mechlorethamine released was
proportional to the time of UV irradiation (Figure 4.1c).

Scheme 4.4 Chemistry of detection of mechlorethamine release from prodrug 4-1 by: (path A)
direct substitution with diethyldithiocarbamate (DDC) and (path B) photolytic fragmentation.

The above mentioned properties of prodrug 4-1 provided a way for the precise control
of the progress of the photolysis reaction with different time courses of UV irradiation to
release active drug 4-4 and fluorescent signaling molecule 4-6.
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4.6 Spectroscopic Properties
The spectroscopic properties of the photolytic reaction were investigated next. These
experiments were performed in a pH 7.4 HEPES buffer.

Both the UV absorption

spectrum and fluorescence emission (λex = 375 nm, λex = 448 nm) were measured before
and after treatment with UV light irradiation (365 nm). The absorption maximum of
prodrug 4-1 is 324 nm (Figure 4.2). After exposure under UV for 15 min, a new
absorption peak, a characteristic of compound 4-6, at 364 nm appeared (Figure 4.2).
Meanwhile, as expected, prodrug 4-1 was originally nonfluorescent due to the presence
of the NPE group and the charged nitrogen moiety in the coumarin (Figure 4.1). The
fluorescence intensity enhancement is proportional to the UV irradiation time (Figures
4.3a and 4.3b). Notably, maximal fluorescence emission was reached within 15 min UV
irradiation with up to 152 folds.

In contrast, no fluorescence intensity change was

observed when prodrug 4-1 was exposed in a pH 7.4 HEPES buffer under ambient light,
indicative of its high stability. Taken together, these findings provide support for the
notion that the photo-controlled release system 4-1 only responses to photo- triggered
cleavage. Moreover, the release event can be readily tracked by fluorescence.
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Figure 4.2. Photolytic activation of 0.1mM fluorescent prodrug 4-1 in pH=7.4 HEPES buffer,
irradiated by a hand-held UV lamp (λ= 365nm). UV-vis spectra in the absence of UV and after 15
min UV exposure.
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Figure 4.3. Photolytic activation of 0.1mM fluorescent prodrug 4-1 in pH=7.4 HEPES buffer,
irradiated by a hand-held UV lamp (λ= 365nm) with different time courses. (a). Fluorescence
spectra. (b). Fluorescence emission enhancement at 448 nm with different UV irradiation time.

4.7 DNA Cross-linking Activity Study
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In the design of a prodrug system, the active parent drug must be released to ensure
biological activity.

It is expected that the UV uncaged bioactive mechlorethamine

produced from prodrug 4-1 upon UV irradiation leads to the subsequent DNA intercross
linking. Therefore, DNA cross linking activity studies were conducted. The experiments
were conducted using linealized plasmid DNA by denaturing alkaline agarose gel
electrophoresis as originally reported by Cech

[50]

. pBR322 plasmid DNA was linearized

by EcoRI restriction endonulease digestion. DNA cross-linking experiment was carried
out in a pH 7.4 Tris-HCl buffer. Due to the inherent toxicity of strong UV light and the
possible UV induced cross link interference, a low-power UV light as light source was
used. It was positioned 75 cm away from the reaction. After 1 h exposure to 365 nm UV
irradiation, cross linking reactions were analyzed on denaturing alkaline agarose gel
electrophoresis by the different mobility of ICL products versus single stranded DNA.
1kb DNA ladder was used as a molecular weight stardard (Figure 4.4, lane 1). Control
reactions were performed with DNA in the absence of prodrug 4-1 treatment both in the
dark (Figure 4.4, lane 2) and with 1 h UV exposure (Figure 4.4, lane 3). Results showed
no noticeable cross-links formation in both cases which suggested that mild UV exposure
for 1 h does not induce DNA cross-links formation. To exclude the possibility that the
UV activated fragment 4-5 was responsible for DNA cross-links formation, control
compound 4-14 was synthesized. According to the photoactivation mechanism,
compound 4-14 was able to release the same fragment 4-5 as prodrug 4-1. Results
indicated that both in the absence (Figure 4.4, lane 4) and presence of UV light (Figure
4.4, lane 5), control compound 4-14 did not induce noticeable cross-link prodructs. The
same result was observed when DNA was treated with 1mM prodrug 4-1 in the absence

91

of UV light (Figure 4.4, lane 6). It indicated that prodrug 4-1 itself without UV exposure
showed negligible activity in forming DNA cross-links. However, in the presence of
prodrug 4-1 (1 mM) with exposure to UV light for 1 hour, efficient DNA cross-link was
observed (Figure 4.4, lane 7), which is comparable to that of the active anticancer drug
mechlorethamine (Figure 4.4, lane 8). These results show that prodrug 4-1 itself the
lacks the cross link activity toward DNA, but can be activated by UV light to generate the
activity by releasing the real drug mechlorethamine, and the other released fragment 4-5
was not responsible for DNA cross-links formation.

1

2

3

4

5

6

7

8

Figure 4.4. DNA cross-links formation with prodrug 4-1/mechlorethamine with exposure to UV
light (365 nm). Lane 1: 1 kb DNA ladder (molecular weight standard). Lane 2: 1 µg pBR322 in
dark (negative control). Lane 3: 1 µg pBR322 with UV treatment for 1 hour. Lane 4: 1 µg
pBR322 with treatment of 1mM control compound 4-14 in dark. Lane 5: 1 µg pBR322 with
treatment of 1mM control compound 4-14 with 1 h UV exposure. Lane 6: 1 µg pBR322 with
treatment of 1 mM prodrug 4-1 in dark. Lane 7: 1 µg pBR322 with treatment of 1 mM prodrug 41 with 1 h UV exposure. Lane 8: 1 µg pBR322 with treatment of 1 mM active drug
mechlorethamine in dark.

4.8 Cell Viability Test
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Before going into cellular tests, we firstly evaluated the stability and cell permeability
of prodrug 4-1. Concerning the fact that prodrug 4-1 is an electrophile, we tested its
stability in a thiol rich cellular environment. As reported, GSH is present at very high
levels in the cytosol, comprising about 90% of nonprotein sulfur with 1-2 mM
concentrations in most of the cells [51]. An aqueous solution containing 5 mM prodrug 4-1
was incubated with 2.0 mM GSH for 6 hours at 37 °C, DDC was incubated for 20 min to
trap the released active drug 4-4. An aliquot of solution was injected to RP-HPLC. We
have not observed decomposition of prodrug 4-1 nor increased amount of compound 4-4,
which showed that prodrug 4-1 was very stable in a GSH rich cellular environment.
To evaluate the cell permeability of prodrug 4-1, 0.8 mM prodrug 4-1 was incubated
with HeLa cells for 2 hours, cell lysate was collected and injected into RP-HPLC,
prodrug 4-1 peak was detected. It supported that prodrug 4-1 was cell permeable.
Having established that prodrug 4-1 is able to release active antineoplastic
mechlorethamine and showed high potency in inducing DNA cross-links. We evaluated
its ability in inhibiting cancer cell growth as well as its cytotoxicity towards normal cells.
Cell viability was measured by using cell counting kit-8 (CCK-8). First of all,
cytotoxicity of prodrug 4-1 was evaluated on normal skin cells (Hekn cell lines). As is
shown in Figure 4.5, without UV exposure on Hekn cells, inactivated prodrug 4-1
showed negligible cytotoxicity towards normal skin cells.

Even with a drug

concentration of 0.8 mM, Hekn cell viability as high as 83.5% was observed. After 30
min UV exposure, activated prodrug 4-1 showed lower cell viability than inactivated
prodrug under the same concentration, but also displays relatively low toxicity towards
normal skin cells, although . Thus, prodrug 4-1 displays low systematic toxicity towards
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normal cells both with and without UV activation. is low toxicity assures its potential for
further study.
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Figure 4.5 Cell viability assays of prodrug 4-1 on normal skin cells (Hekn cell lines). Prodrug 4-1
was incubated with the cells for 2 h followed by 30 min UV irradiation. The cell viability was
measured after 24 h after incubation using cell counting kit-8 (CCK-8).

Next, cell viability was evaluated with prodrug 4-1 on cancer cells (HeLa cell lines).
First of all, as is shown in Figure 4.6, prodrug 4-1 activated by 30 min UV irradiation
showed significant greater potential in killing cancer cells than inactive prodrug 4-1 itself.
With an increasing drug dosage, a larger amount of cancer cells (HeLa cells) was killed.
Meanwhile, we have observed an impressive selectivity towards cancer cells. With a
drug concentration of 0.8 mM, 27.8% cell viability on HeLa cells compared with 83.5%
cell viability on Hekn cells.

This might be explained by the ICL property of the

inhibition mechanism. Cancer cells generally grow and divide at a much faster rate than
normal cells. It is expected that much higher DNA replication and transcription activities
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take place in cancer cells than those in normal cells, thus cell growth inhibition by
intercross links formation is much more efficient towards cancer cells, accounting for the
selectivity of the prodrug 4-1.
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Figure 4.6 Cell viability assays of prodrug 4-1 on cancer cells (HeLa cell lines) Prodrug 4-1 was
incubated with the cells for 2 h followed by 30 min UV irradiation. The cell viability was
measured after 24 h after incubation using cell counting kit-8 (CCK-8).

During the drug release process, both mechlorethamine 4-4 and quinone methide type
compound 4-5 were produced. As quinone methide was reported to exhibit DNA
alkylating ability , we made control compound 4-14 to further investigate drug action
mechanism. Compound 4-14 is different from prodrug 4-1 for it has the inactive 2,2'(methylazanediyl)diethanol incorporated instead of the active drug mechlorethamine. As
is shown in Figure 4.7, with dosage at 0.8 mM, control compound 4-14 exhibit weaker
potential in killing cancer cells compared with prodrug 4-1 both in the presence and
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absence of UV irradiation. Thus, it confirmed that the anticancer ability of prodrug 4-1
was mainly due to the release of mechlorethamine 4-4 instead of quinone methide type
compound 4-5.
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Figure 4.5. Cell viability assays of prodrug 4-1 and control compound 4-14 on cancer cells
(HeLa cell lines) Prodrug 4-1 and control compound 4-14 were incubated with the cells for 2 h
followed by 30 min UV irradiation. The cell viability was measured after 24 h incubation using
cell counting kit-8 (CCK-8).

4.9 Fluorescence Imaging Study
Having demonstrated that the prodrug can release the active drug form, next we
evaluate the second feature of the prodrug 4-1. It is designed for fluorescent monitoring
of photoactivated drug release in cells. Prodrug 4-1 was incubated with HeLa cells for 2
hours for cellular uptake, followed by 30 min UV exposure to release active drug 4-4 and
the fluorescent signal molecule 4-6. As is shown in Figure 4.6, HeLa cells exhibited
strong fluorescence only with photoactivated prodrug (Figure 4.6 a). In the absence of
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either prodrug 4-1 or UV light, no fluorescence was observed (Figure 4.6 b and 4.6 c).
These results clearly showed that the prodrug 4-1 was cell permeable and the
fluorescence signals reflected the process of UV activated drug release.

a

b

c

d

Figure 4.6. Fluorescence images of HeLa cells using an Olympus IX71 ﬂuorescence microscope.
(a) Fluorescence image of HeLa cells treated with prodrug 4-1 (350 μM) for 2 h followed by 30
min UV exposure; (b) Fluorescence image of HeLa cells treated with prodrug 4-1 (350 μM) for 2
h in the absence of UV light, total incubation period of 2.5 h; (c) Fluorescence image of HeLa
cells in the absence of prodrug 4-1 only with 30 min UV exposure. The total incubation time is
2.5 h; (d) Fluorescence image of HeLa cells in the absence of prodrug 4-1 (350 μM) and without
UV exposure.

To track the intracellular internalization and localization of prodrug 4-1, we incubated
it with HeLa cells at different times.

The prodrug is cell permeable and nucleus
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permeable (Figure 4.7). It was found that its distribution is time dependant and nucleus
selective presumably due to its positive charged characteristic. The prodrug moves from
cytoplasm to nuclei as incubation time prolongs. In a short incubation time (20 min),
fluorescence was mainly observed in the cytoplasm upon UV irradiation, while 1 h, the
signal was seen both in the cytoplasma and nuclei region. Longer incubation time (2 h)
leads to stronger fluorescence in the nuclei region. The studies offer the important
information of optimal time for the delivery of the drug at the desired site. Prodrug 4-1 is
able to be monitored by convenient fluorescent tracking of drug localization in a
spatiotemporal manner. Furthermore, the ability of controlled drug release into nuclei
maximizes the DNA cross-linking efficiency.

a

b

c

Figure 4.7. Fluorescence images of HeLa cells treated with 350 μM prodrug 4-1 followed by 30
min UV irradiation. HeLa cells were incubated with prodrug 4-1, after 30 min UV irradiation,
cells were fixed and stained with propidium iodide (red) for nuclei and prodrug 4-1 (blue) for the
site of action. a) Fluorescence image of UV activated prodrug 4-1; b) Fluorescence image of
nuclei; c). Merged image of a and b.

4.10 Summary
In conclusion, we developed a novel dual functional photo-triggered fluorescent
prodrug for anticancer drug releasing and monitoring. The release of the active DNA
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alkylator mechlorethamine can be controlled with UV irradiation, accompanied with a
maximum of 152 fold fluorescence increase.

Moreover, we demonstrated that the

photolytic product was able to induce effective DNA cross-linking activities which
account for its anticancer activity. Prodrug 4-1 showed negligible cytotoxicity towards
normal skin cells (Hekn cells) with and without UV activation.

Nonetheless, the

activated prodrug 4-1 exhibits potent anticancer activity towards cancer cells.
Furthermore, importantly, the drug release progress can be conveniently monitored by the
fluorescence enhancement in cells.

Fluorescence imaging experiment showed that

prodrug 4-1 is not only cell permeable but also nuclear permeable and selective.
Therefore, these studies demonstrate that the prodrug could serve as a promising drug
delivery system for spatiotemporal control release and monitoring of an anticancer drug
to maximize the treatment efficacy in personalized medicine.

4.11 Experimental Section
General Information
All reactions were carried out in dried flasks. The reactions were monitored by TLC for
completion. Commercially available reagents were used as received without further
purification unless otherwise specified. Merck 60 silica gel was used for column
chromatography, and Whatman silica gel plates with fluorescence F254 were used for
thin-layer chromatography (TLC) analysis.

1

H and

13

C NMR spectra were recorded on

Bruker Avance 500 or 300. Data for 1H are reported as follows: chemical shift (ppm), and
multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet). Data for
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13

C

NMR are reported as ppm. Mass Spectra were obtained from University of New Mexico
Mass Spectral facility.

Synthesis of prodrug 4-1

Compound 4-1 was synthesized following the procedures in Scheme 4-2

HO

O

O

7-Hydroxy-8-methyl-2H-chromen-2-one (4-8)
A mixture of equimolar amount of 2-methylbenzene-1,3-diol (2.48 g, 20.0 mmol) and 2hydroxysuccinic acid (2.48 g, 20.0 mmol) with 3.0 equiv. of concentrated sulfuric acid
(5.88 g, 3.2 mL, 60 mmol) was exposed to mircrowave irradiation (240W, 120 °C) for 4
min. The reaction mixture was extracted with ethyl acetate and water. After solvent
evaporation, the crude product was purified by silica gel column chromatography to give
brown yellow solid as product (2.53 g, 72% yield). 1H NMR (CD3OD, 300 MHz): δ 7.75
(d, J = 9.3 Hz, 1H), 7.22 (d, J = 8.4 Hz, 1H), 6.75 (d, J = 8.4 Hz, 1H), 6.11 (d, J = 9.3 Hz,
1H), 2.20 (s, 3H).

AcO

O

O

8-Methyl-2-oxo-2H-chromen-7-yl acetate (4-9)
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7-Hydroxy-8-methyl-2H-chromen-2-one (1.76 g, 10 mmol) was dissolved in acetic
anhydride (20.4 g, 200 mmol) and immersed in an ice water bath. After the addition of
pyridine (948 mg, 12 mmol), the reaction mixture was stirred at rt for 12 h. Excess acetic
anhydride was removed under reduced pressure.

Residue was dissolved in

dichloromethane, washed with saturated sodium bicarbonate, water, dried over sodium
sulfate. The crude product was further purified by silica gel column chromatography to
give (2.18 g, quantitative yield) white solids as product. 1H NMR (CDCl3, 300 MHz): δ
7.66 (d, J = 9.6 Hz, 1H), 7.31 (d, J = 8.4 Hz, 1H), 6.97 (d, J = 8.4 Hz, 1H), 6.35 (d, J =
9.6 Hz, 1H), 2.34 (s, 3H), 2.25 (s, 3H).

AcO

O

O

Br

8-(Bromomethyl)-2-oxo-2H-chromen-7-yl acetate (4-10)
8-Methyl-2-oxo-2H-chromen-7-yl acetate (2.18 g, 10.0 mmol) was dissolved in 15 mL of
carbon tetrachloride, then NBS (2.136 g, 12.0 mmol) was added to the reaction mixture
followed by AIBN (49 mg, 0.2 mmol). The reaction mixture was stirred under reflux for
6 hours. After solvent removal under reduced pressure, the crude product was further
purified by silica gel column chromatography to give light yellow solid as product (2.25
g, 76% yield). 1H NMR (CDCl3, 300 MHz): δ 7.67 (d, J = 9.6 Hz, 1H), 7.44 (d, J = 8.4
Hz, 1H), 7.08 (d, J = 8.4 Hz, 1H), 6.38 (d, J = 9.6 Hz, 1H), 4.63 (s, 2H), 2.40 (s, 3H). 13C
NMR (CDCl3, 300 MHz): δ 168.17, 159.38, 152.20, 151.47, 142.95, 128.24, 119.28,
118.59, 116.69, 115.98, 20.83, 19.05.
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HO

O

O

OH

7-Hydroxy-8-(hydroxymethyl)-2H-chromen-2-one (4-11)
A mixture of calcium carbonate (2.6 g, 26 mmol) in 12 mL of water was added to a
solution of 8-(bromomethyl)-2-oxo-2H-chromen-7-yl acetate (1.468 g, 5.0 mmol) in 12
mL of dioxane. The mixture was stirred at 50 °C for 24 h. Dioxane was removed under
reduced pressure to give a white solid. After extraction using ethyl acetate and 2M HCl,
the crude product was further purified by silica gel column chromatography to give white
solids as product (936 mg, 80% yield). 1H NMR (acetone-d6, 300 MHz): δ 9.62 (s, 1H),
7.84 (d, J = 9.6 Hz, 1H), 7.43 (d, J = 8.7 Hz, 1H), 6.82 (d, J = 8.4 Hz, 1H), 6.15 (d, J =
9.6 Hz, 1H), 5.02 (s, 2H), 2.02 (d, J = 6.0 Hz, 1H). 13C NMR (acetone-d6, 300 MHz): δ
161.11, 160.85, 153.87, 145.08, 129.13, 114.57, 113.95, 112.62, 112.55, 56.05. ESI-MS:
[M+H] calculated for C10H9O4: 193.05; found: 193.05. m.p. : 158-160 °C.

O
NO2

O

O

OH

8-(Hydroxymethyl)-7-(2-nitrobenzyloxy)-2H-chromen-2-one (4-12).
Potassium carbonate (662 mg, 4.8 mmol) was dissolved in 25 mL of acetonitrile,
followed by the addition of 7-hydroxy-8-(hydroxymethyl)-2H-chromen-2-one (936 mg, 4
mmol) and 1-(bromomethyl)-2-nitrobenzene (1046 mg, 4.8 mmol). The reaction mixture
was stirred in dark at 50 °C for 5 h. After solvent removal under reduced pressure, the
crude product was further purified by silica column chromatography to give white solids
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as product (968 mg, 74% yield). 1H NMR (CDCl3, 300 MHz): δ 8.22 (d, J = 8.1 Hz, 1H),
7.90 (d, J = 7.8 Hz, 1H), 7.65 (m, 2H), 7.56 (m, 1H), 7.42 (d, J = 8.7 Hz, 1H), 6.94 (d, J
= 8.7 Hz, 1H), 6.31 (d, J = 9.6 Hz, 1H), 5.64 (s, 2H), 5.07 (d, J = 6.0 Hz, 2H), 2.35 (t, J =
6.9 Hz, 1H). [M+H] calculated for C17H14NO6: 328.08; found: 328.08. m.p.: 212-214 °C.

O
NO2

O

O

Br

8 (8-(Bromomethyl)-7-(2-nitrobenzyloxy)-2H-chromen-2-one) (4-13):
A solution of tribromophosphine (643 mg, 226 μL, 2.4 mmol) in 2.0 mL of anhydrous
dichloromethane was added dropwise to a solution of 8-(hydroxymethyl)-7-(2nitrobenzyloxy)-2H-chromen-2-one (654 mg, 2 mmol) in 10 mL of anhydrous
dichloromethane over 30 min with the temperature between -5 °C and -3 °C. The
reaction mixture was stirred in dark at rt for 40 min. After the reaction is complete, it was
washed with brine, concentrated and run column to give white solids as product (599 mg,
77% yield). 1H NMR (CDCl3, 300 MHz): δ 8.23 (d, J = 2.5 Hz, 1H), 8.04 (d, J = 7.8 Hz,
1H), 7.76 (d, J = 7.2 Hz, 1H), 7.65 (d, J = 9.6 Hz, 1H), 7.55 (d, J = 7.8 Hz, 1H), 7.43 (d,
J = 8.7 Hz, 1H), 6.92 (d, J = 8.7 Hz, 1H), 6.32 (d, J = 9.6 Hz, 1H), 5.69 (s, 2H), 4.88 (s,
2H).

13

C NMR (CDCl3, 300 MHz): δ 160.15, 158.64, 152.91, 146.71, 143.25, 134.50,

132.59, 129.23, 128.78, 128.32, 125.21, 114.58, 114.07, 113.51, 108.60, 67.57, 20.22.
ESI-MS: [M+H] calculated for C17H13BrNO5: 390.00; found: 390.00. m.p.: 210-212 °C.
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O
NO2

O
N+

O
OH

BrOH

2-Hydroxy-N-(2-hydroxyethyl)-N-methyl-N-((7-(2-nitrobenzyloxy)-2-oxo-2Hchromen-8-yl)methyl)ethanaminium bromide (4-14)
A solution of 8-(bromomethyl)-7-(2-nitrobenzyloxy)-2H-chromen-2-one (389 mg, 1.0
mmol) and 2,2'-(methylazanediyl)diethanol (357 mg, 3.0 mmol) in 10 mL of anhydrous
acetonitrile was stirred in dark at rt for 12 h. After filtration, white solids were obtained
as product (309mg, 61% yield).

1

H NMR (DMSO-d6, 300 MHz): δ 8.21 (d, J = 8.1 Hz,

1H), 8.07 (d, J = 9.6 Hz, 1H), 7.89 (d, J = 8.7 Hz, 1H), 7.81 (m, 2H), 7.68 (m, 1H), 7.29
(d, J = 9.0 Hz, 1H), 6.42 (d, J = 9.6 Hz, 1H), 5.71 (s, 1H), 5.25 (t, J = 4.8 Hz, 2H), 4.84 (s,
2H), 3.89 (m, 4H), 3.64 (m, 2H), 3.46 (m, 2H), 3.02 (s, 3H). ESI-MS: [M+H] calculated
for C22H25N2O7: 429.17; found: 429.17. m.p.: 195-196 °C.

O
NO2

O
N+ BrCl

O
Cl

2-Chloro-N-(2-chloroethyl)-N-methyl-N-((7-(2-nitrobenzyloxy)-2-oxo-2H-chromen8-yl)methyl)ethanaminium bromide (4-1)
2-Hydroxy-N-(2-hydroxyethyl)-N-methyl-N-((7-(2-nitrobenzyloxy)-2-oxo-2H-chromen8-yl)methyl)ethanaminium bromide (254 mg, 0.5 mmol) was dissolved in 10 mL of
thionyl chloride. The reaction mixture was stirred at rt for 3 d. After solvent evaporation
under reduced pressure, white solid was obtained as product (272 mg, quantitative yield).
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1

H NMR (DMSO-d6, 300 MHz): δ 8.21 (d, J = 8.1 Hz, 1H), 8.08 (d, J = 9.3 Hz, 1H), 7.90

(d, J = 8.7 Hz, 1H), 7.78 (m, 2H), 7.67 (m, 1H), 7.28 (d, J = 8.7 Hz, 1H), 6.43 (d, J = 9.3
Hz, 1H), 5.74 (s, 2H), 4.88 (s, 2H), 4.17 (m, 4H), 3.86 (m, 4H), 3.15(s, 3H).

13

C NMR

(DMSO-d6, 300 MHz): 160.33, 158.95, 154.73, 147.23, 144.39, 134.32, 132.85, 131.31,
129.54, 129.45, 125.14, 113.56, 113.37, 109.98, 103.54, 68.21, 61.64, 55.03, 48.07, 36.51.
ESI-MS: [M+H-Br] Calculated for C22H23Cl2N2O5: 465.10, found 465.10. m.p.: 95-96 °C.

HPLC monitoring of drug release
(a)

(b)

(c)
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Figure S1. HPLC monitoring of drug release of prodrug 4-1. (a) 0 min; (b) 28 min; (c) 85 min.
Photolytic activation of 0.1 mM fluorescent prodrug 4-1 in pH = 7.4 HEPES buffer, irradiated by
a hand-held UV lamp (λ= 365 nm).

Prodrug 4-1 (2.0 mM) was dissolved in an aqueous solution of MeCN/H2O (20:80), a
hand-held UV lamp (365 nm, 2W) was positioned 10 cm away from the reaction vial as
light source. After designated reaction time, an aliquot of 20 μL solution was taken and
submitted to RP-HPLC to be analyzed by a 254 nm UV detector, the amount was
integrated by the area under each peak, and calculated from the standard curves under the
same HPLC condition.
HPLC condition: Eclipse XDB-C8 column, flow rate is 0.8 mL/min, 0-20 min:
MeCN/H2O (10:90), 20-40 min: MeCN/H2O (30:70).

Protocol of study of UV irradiation reaction of prodrug 4-1
Prodrug 4-1 (13 mg) was dissolved in 239.2 μL of DMSO and 2152.8 μL of PBS buffer
to make a solution of 10 mM. A hand-held UV lamp (365 nm, 2W) was positioned 10
cm away from the reaction vial as light source. Reaction was complete in 90 min,
extracted with ethyl acetate and water, after solvent removal, the crude mixture was
submitted to column chromatograph to obtain 1.5 mg white solids as product (isolated
yield of 71%). 1H NMR (acetone-d6, 300 MHz): δ 9.62 (s, 1H), 7.84 (d, J = 9.6 Hz, 1H),
7.43 (d, J = 8.7 Hz, 1H), 6.82 (d, J = 8.4 Hz, 1H), 6.15 (d, J = 9.6 Hz, 1H), 5.02 (s, 2H),
2.02 (d, J = 6.0 Hz, 1H).

13

C NMR (acetone-d6, 300 MHz): δ 161.11, 160.85, 153.87,

145.08, 129.13, 114.57, 113.95, 112.62, 112.55, 56.05. ESI-MS: [M+H] calculated for
C10H9O4: 193.05; found: 193.05.
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Spectroscopic materials and methods
Millipore water was used to prepare all aqueous solutions. The pH was recorded by a
Beckman ΦTM 240 pH meter. UV absorption spectra were recorded on a Shimadzu UV1800 spectrophotometer. Fluorescence emission spectra were obtained on a Shimadzu
RF-5301PC spectrofluorophotometer. Prodrug 4-1 in DMSO (10 mM) was prepared as
the stock solution, 50 μL of the stock solution was added to 4.950 mL of 20 mM pH 7.4
HEPES buffer to make the final concentration of 0.1 mM. A hand-held UV lamp (365
nm, 2W) was positioned 10 cm away from the reaction vial as light source. Change in
fluorescence emission (λex = 375 nm, λem = 448 nm) and UV-vis spectra were measured
at designated time interval.

Preparation of cell cultures
HeLa cell line was purchased from American Type Culture Collection. The cells were
cultured in DMEM containing 10% FBS and 1% (v/v) antibiotic-antimycotic solution at
37 C with 95% air/5% CO2 in an incubator.

Human Epidermal Keratinocytes (HEKn) cells were obtained from Lifeline Cell
Technology. The cells were cultured in DermaLife Basal Medium (DermaLife K Medium
Complete Kit) at 37 C with 95% air/5% CO2 in an incubator.

Interstrad DNA cross-links formation study
General Procedure for Linearization of Plasmid pBR322 by EcoRI.
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pBR322 Vector(New England Biolabs) (28µL, 28 µg) was incubated with EcoRIHF(New England Biolabs) (20 µL),EcoR1 buffer (10 ×, 20 µL), and 132 µL of H2O
(sterile) for 3 h at 37 °C. NaOAc (20 µL, 3M) and ethanol (750 µL) were added, and the
solution was cooled at -20 °C overnight. The mixture was centrifuged for 15 min at
16000 rpm, and the ethanol was decanted off. The remainder of the ethanol was
evaporated off in vacuo at -20°C , and the remaining linearized DNA was suspended in
100 µLof sterile H2O. The amount of linearized pBR322 was quantitated by
NANODROP 2000 spectrophotometer (Thermo Scientific).

Photoreaction of DNA with prodrug 4-1, control compound 4-14, or
mechloethamine.
Solutions contained 1 µg linearized plasmid DNA in 0.15 M NaCl, 0.01 M Tris-HCl, and
0.001 M EDTA, pH 7.4. 10mM stock solution of prodrug 4-1 or control compound 4-14
or mechloethamine was added to a final concentration of 1mM, obtaining a final volume
of 50 μL. The Interstrad DNA cross-link formation reactions were conducted 75 ± 5 cm
away from UV light (30 W g30t8 bubble from General Electronic Company). After 1
hour incubation, the reaction solution was submitted to alkaline agarose gel
electrophoresis.

General Protocol for Alkaline Agarose Gel Electrophoresis.
The agarose gels were prepared by adding 150 mL of a 50 mM NaCl / 2 mM EDTA (at
pH = 8.0) to 1.8 g of agarose. The suspension was heated in a microwave oven until all of
the agarose was dissolved(3 min). The gel was allowed to cool until 50°C and poured and
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solidified for 1h at room temperature. The gel was soaked in an alkaline running buffer
(25 mL of 2 N NaOH, 4 mL of 0.25 M EDTA in 1 L of H2O). Agarose loading dye (New
England Biolabs) (6 x, 10 µL) was added to the samples (50 µ L) , and the samples were
loaded into the wells. The gel was run for 3 h at 200 mA/30 V. The gel was then
neutralized for 45 min in a 1 M Tris pH = 7/1.5 M NaCl solution, which was refreshed
every 15 min. The gel was subsequently stained in an ethidium bromide solution (100 µ
L of a 10 mg/ mL ethidium bromide solution in 1 L of 1 M Tris /1.5 M NaCl buffer at
pH = 7.5) for 1 h. Gels were visualized by UV and photographed using Gel Doc™ XR+
System(BIO-RAD).

Cell viability test
Cell viability was measured by using cell counting kit-8 (CCK-8), which quantitatively
measures activities of dehydrogenases in cells. Cells (5  103 cells/well) were seeded
into 96-well microtiter plates.

Following treatment with prodrug 4-1 and different

reaction conditions (in the presence or absence of 365 nm UV light), 10 μL of CCK-8
solution was added to each well of the plate. The plate was placed into the incubator at 37
C with 95% air/5% CO2. After one hour incubation, the absorbance was measured at
450 nm in a Bio-Rad 3350 microplate reader. Cells without any treatment were used as
100% cell viability. The cell viability was calculated by using the formula: Cell viability
= (Experimental absorbance value – culture medium absorbance value)/(without
treatment absorbance value – culture medium absorbance value).

Fluorescence imaging of photoactivated prodrug 4-1

109

HeLa cells were plated onto polylysine-coated glass coverslips. After reaching 70%
confluence, 350 μM prodrug was added to Hela cells, incubated for 2 h before 30 min
UV exposure. Next, cells were washed thoroughly by DMEM. The coverslips were
mounted on a glass slide. Images were acquired using an inverted microscope with a
DAPI dichroic mirror.

Fluorescence subcellular imaging of photoactivated prodrug 4-1
HeLa cells were plated onto polylysine-coated glass coverslips. After reaching 70%
confluence, cells were incubated with prodrug 4-1 for 30 min, followed by 30 min UV
exposure. Cells were then washed 3 times with warmed DMEM medium, fixed with 4%
paraformaldehyde for 15 min at room temperature (RT) and washed with PBS again. For
counter staining, cells were permeabilized with 0.1% Triton-X100 for 10 min and rinsed
with PBS again. Nuclei were labeled using propidium iodide (10 mg/mL) and cover
glasses were mounted by AntifadeH mounting media. All slides were kept in dark until
fluorescence images were acquired using an inverted microscope with a DAPI dichroic
mirror for prodrug imaging and DSRED dichroic mirror for nuclei stain image.
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